University of Kentucky

UKnowledge
Theses and Dissertations--Neuroscience

Neuroscience

2016

NOVEL TARGETS FOR MITOCHONDRIAL DYSFUNCTION
FOLLOWING TRAUMATIC BRAIN INJURY
Heather M. Yonutas
University of Kentucky, heather.yonutas@uky.edu
Digital Object Identifier: http://dx.doi.org/10.13023/ETD.2016.027

Right click to open a feedback form in a new tab to let us know how this document benefits you.

Recommended Citation
Yonutas, Heather M., "NOVEL TARGETS FOR MITOCHONDRIAL DYSFUNCTION FOLLOWING TRAUMATIC
BRAIN INJURY" (2016). Theses and Dissertations--Neuroscience. 15.
https://uknowledge.uky.edu/neurobio_etds/15

This Doctoral Dissertation is brought to you for free and open access by the Neuroscience at UKnowledge. It has
been accepted for inclusion in Theses and Dissertations--Neuroscience by an authorized administrator of
UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.

STUDENT AGREEMENT:
I represent that my thesis or dissertation and abstract are my original work. Proper attribution
has been given to all outside sources. I understand that I am solely responsible for obtaining
any needed copyright permissions. I have obtained needed written permission statement(s)
from the owner(s) of each third-party copyrighted matter to be included in my work, allowing
electronic distribution (if such use is not permitted by the fair use doctrine) which will be
submitted to UKnowledge as Additional File.
I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and
royalty-free license to archive and make accessible my work in whole or in part in all forms of
media, now or hereafter known. I agree that the document mentioned above may be made
available immediately for worldwide access unless an embargo applies.
I retain all other ownership rights to the copyright of my work. I also retain the right to use in
future works (such as articles or books) all or part of my work. I understand that I am free to
register the copyright to my work.
REVIEW, APPROVAL AND ACCEPTANCE
The document mentioned above has been reviewed and accepted by the student’s advisor, on
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of
the program; we verify that this is the final, approved version of the student’s thesis including all
changes required by the advisory committee. The undersigned agree to abide by the statements
above.
Heather M. Yonutas, Student
Dr. Patrick G. Sullivan, Major Professor
Dr. Wayne A. Cass, Director of Graduate Studies

NOVEL TARGETS FOR MITOCHONDRIAL DYSFUNCTION FOLLOWING
TRAUMATIC BRAIN INJURY
________________________________________________________________
DISSERTATION
________________________________________________________________
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy in the College of Medicine at the University of Kentucky
By
Heather Marie Yonutas
Lexington, Kentucky
Director: Dr. Patrick G Sullivan,
Professor of Anatomy & Neurobiology,
Endowed Chair Spinal Cord & Brain Injury Research Center
Lexington, Kentucky
2016
Copyright © Heather Marie Yonutas 2016

ABSTRACT OF DISSERTATION

NOVEL TARGETS FOR MITOCHONDRIAL DYSFUNCTION FOLLOWING
TRAUMATIC BRAIN INJURY
Mitochondrial dysfunction is a phenomenon observed in models of
Traumatic Brain Injury (TBI). Loss of mitochondrial bioenergetics can result in
diminished cellular homeostasis leading to cellular dysfunction and possible
cellular death. Consequently, the resultant tissue damage can manifest as
functional deficits and/or disease states. Therapeutic strategies to target this
mitochondrial dysfunction have been investigated for models TBI and have
shown promising effects.
For this project, we tested the hypothesis that mitoNEET, a novel
mitochondrial membrane protein, is a target for pioglitazone mediated
neuroprotection. To test this, we used a severe Controlled Cortical Impact (CCI)
injury model in mitoNEET null and wild-type mice. We then dosed these animals
with pioglitazone or NL-1, which is a compound that has a similar structure to
pioglitazone allowing us to hone in one the importance of mitoNEET binding.
Wild-type animals treated with the mitoNEET ligands, both pioglitazone and NL1, had improved mitochondrial function, tissue sparing and functional recovery,
compared to mitoNEET null animals.
In addition to this specific hypothesis tested, our experiments provided
insight casting doubt on the central dogma that mitochondrial dysfunction
following TBI is the result of vast oxidative damage and consequential
irreversible mitochondrial loss. The data from these studies show that when
mitoNEET is targeted with pioglitazone at 12 hours’ post-injury, mitochondrial
dysfunction can be reversed. Additionally, when bypassing proteins upstream of
Complex I with an alternative biofuel, such as beta-hydroxybuterate (BHB), TBI
related mitochondrial dysfunction is once again reversed. This leads to novel
hypothesis for future work which posits mitoNEET as a redox sensitive switch;
when mitoNEET senses changes in redox, as seen in TBI, it inhibits
mitochondrial respiration. When targeted with an agonist/ligand or bypassed with
a biofuel TBI mitochondrial dysfunction can be reversed.
These studies support the role of mitoNEET in the neuropathological
sequelae of brain injury, supporting mitoNEET as a crucial target for pioglitazone
mediated neuroprotection following TBI. Lastly, these studies propose a

mechanism of TBI related mitochondrial dysfunction which can reversed with
pharmacological agents.
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CHAPTER 1: THE POWERHOUSE OF THE CELL: MITOCHONDRIA
Mitochondria are key to cellular energetics and cellular homeostasis and
have profound implications in the initiation of cell death. The study of these
microscopic organelles has provided fundamental insights into the workings of a
cell that covers a broad spectrum from genetics to biophysics to cell biology.
Studies have a demonstrated their importance in various neurodegenerative
diseases and have been linked to the secondary injury cascade following a brain
injury. For these reasons, mitochondria occupy a central position in the science
of Cell Biology and Neurobiology.
Neuronal homeostasis and function has been found to be dependent on
mitochondrial bioenergetics. As the “Power Plant” of the cell, mitochondria
provide 90 to 95% of the energy needed for the cell to function properly [1-8]. As
mitochondria become dysfunctional, cellular dysfunction soon follows. Therefore,
research has focused on the discovery of pharmaceutical interventions that
target mitochondrial dysfunction associated with various diseased states. Many
therapeutic interventions that target mitochondrial function is these diseased
states have shown positive results. One disease model that is characterized by
vast mitochondrial dysfunction and has shown improved outcome when
dysfunctional mitochondria are targeted is Traumatic Brain Injury, TBI. In this
chapter there will be a historical overview of mitochondria in the scientific
literature. Mitochondrial bioenergetics and their importance to proper brain
function will also be discussed. The following chapters will explain cell specific
and age related changes that occur within mitochondria with a detailed
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explanation into the pathobiology of traumatic brain injury. Further details will
also be provided on therapeutic interventions that target mitochondria leading to
improved outcomes.
History of Mitochondria
Mitochondria have a very rich history in the scientific literature. They have
been a subject of study for many Nobel Prizes, demonstrating their importance
to overall cellular homeostasis. Although their history is rich, the time between
initial observations of mitochondria and the understanding into their functions
was long, initially being overshadowed by the discovery of the nucleus. The first
official observations of mitochondria date back to the 1841 when cytologist
Jakob Henle observed mitochondria in the muscles of insects [9-11]. In 1856,
Von

Kölliker,

a

Swiss

Anatomist

and

Physiologist,

described

this

“sarcomere”/organelle with more detail during his studies in spermatogenesis
[12]. However, at this point, the function of these unknown intracellular
structures was still ill defined, at the time hypothesized as a physical structure
that had a role in the transmission of genetic information.
Remarkably, in the 1890s, Richard Altmann termed these intracellular
granules “bioplasts” and proposed them to be autonomous, forming bacteriallike colonies within their host cells [13]. Based on our current knowledge and the
evolutionary theory of a prokaryotic and eukaryotic symbiosis being formed
billions of years ago, this was indeed a very astute observation. However their
significance was still unappreciated [14-16]. Scientists in the field continued to
described these intracellular structures by terms like “chondros”, “Korn” and
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“grain’. Then, in 1898, with the development of improved staining techniques,
the Greek term “mitos” was adopted by Carl Benda leading to the new term
“mitochondria” [review by Chowdry 1918, quoted in [17] and [13].
Following the discovery of these organelles from a physical perspective,
much time passed in the scientific literature before mitochondria were brought up
by name again. However, during this down time, researchers were on track for
some big findings due to continued progress in the field of cellular metabolism
and cellular respiration. Dehydrogenase studies completed by Battelli and
Sterns, which was later expanded upon by Heinrich Otto Wieland, and the
discovery of insoluble iron containing “respiratory enzymes” (Atmungsferment,
which are ironcolloid complexes) by Otto Heinrich Warburg lead to the initial
findings which gave insoluble cellular enzymes credit for cellular respiration.
However, these founding studies were also followed by great debate. Due to his
work with iron containing molecules, Warburg hypothesized that cellular
respiration was mediated through oxygen transfer between enzymes. Wieland,
due to his investigations into dehydrogenases, believed respiration was mediated
through hydrogen transfers. Then, in 1925, David Keilin, during his research
involving cytochromes, provided deeper insight into the understanding of the
electron transport chain that included dehydrogenases at one end and
Atmungsferments (ironcolloids) are the other end, ending the current debate
between Weiland and Warburg. Further research was completed by David Keilin,
and his understudy E. F. Hartree, leading to the acknowledgement of an
“unspecific colloidal structure” which localized these respiratory enzymes that
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were the topic of such great debate. It wasn’t until work from Cleland and Slater
in the 1950s that these “unspecific colloidal structures” were defined as
phospholipids in the membrane of the mitochondria. Additionally, the
dehydrogenases that were upstream to the ironcollloid structures were eventually
defined by Hans Adolf Krebs as the Citric Acid Cycle, which is often called the
Krebs Cycle.
When attempting to understand the importance of mitochondria a
discussion about adenosine triphosphate, ATP, is crucial. ATP is a crucial
macromolecule in the cell with an importance debated as second to DNA. It was
first discovered in 1929 by a German Chemist name Karl Lohmann. However, it
wasn’t until the work of Vladimir Engelhart, in 1935, and then Fritz Lipmann in the
early 40s, that this compound was credited for many important functions in the
cell. Work from Engelhart showed that ATP was necessary for proper muscle
contraction. Building upon that, Lipmann was then credited for coining the term
“energy-rich phosphate bonds” when he discovered that ATP is the main bearer
of chemical energy for the cell. Now, it is well accepted that ATP is made up of
the nucleoside adenosine that is bound to three phosphate groups.
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Figure 1.1 Chemical Equation for Hydrolysis of ATP: Hydrolysis of ATP leads
to the generation of 30.5 kJ/mol of energy plus an ADP molecule and a free
inorganic phosphate. [18]
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Upon the removal of the outermost, third, phosphate group, adenosine
diphosphate (ADP) is formed. The cleavage of this phosphate group leads to the
release of ~30.5 kJ/mol of energy. Conversely, generating an ATP molecule
requires an ADP molecule with the addition of an inorganic phosphate group,
which is more often than not completed in the mitochondria. Large quantities of
ATP are formed and consumed in the human body daily. One report made the
assumption that the average adult male has approximately 1 trillion metabolically
active cells in the body. Each cell contains roughly 1 billion ATP molecules at any
given time. With these values, one can calculate 1023 ATP molecules in the
human body at any given time [19]. As mentioned previous, 90-95% of these
ATP made in the body is carried out within the mitochondria by the enzyme ATP
synthase, leading into further insight into the importance of these, once ill
defined, organelles.
The time of the discovery of ATP, Warburg sought out to discover how
these molecules were made. Keeping in mind that he was a proponent of
oxidative phosphorylation, he attempted to describe the production of ATP
through substrate level phosphorylation in which an ATP molecule was produced
as a result of the enzymatic oxidation of a specific compound. As we currently
understand cellular metabolism, his hypothesis was not wrong since we do
observe substrate phosphorylation during glycolysis and the Krebs cycle.
However, this process does not account for the majority of ATP made by the cell.
Conversely, H.M. Kalckar proposed a separate method to explain ATP
production. He hypothesized that the process of phosphorylating ADP to
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generate ATP was linked respiration. Specifically, the energy generated in the
process of oxidizing the nutrients within our bodies was harnessed to make ATP,
which is a process now termed oxidative phosphorylation [20-25]. As we know,
this method is favored in cells with active mitochondria.
About the time that progress was being made in the field of ATP and ATP
production,

Albert

Claude

pioneered

a

separation

technique

allowing

researchers to isolate functioning mitochondria. Within this technique he defined
the appropriate buffers and tissue fractionation method based on differential
centrifugation [26-31]. These techniques were then applied by Albert L.
Lehninger and his group to further validate his previous work concluding that
fatty acid oxidation is primarily completed in the mitochondria and that the rate
of reactions within the citric acid cycle was high enough to provide the majority
of energy to liver cell [32-38]. This observation has never been disproven
considering that mitochondria function within liver cells is known to be very high.
During these studies, they also determined that fatty acid oxidation and citric
acid cycle activity lead to ATP production in a manner that was dependent on
oxidative phosphorylation, confirming Klackar’s previous work [35].
With the invention of electron microscopes in the earlier 50s, the structure
of mitochondria could be better defined. It is now well accepted that
mitochondria are intracellular organelles with a dual (inner and outer) membrane
system, each responsible for specific functions.
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Cristae

Figure 1.2 An electron micrograph of mitochondria: This image shows the
dual membrane nature and intact cristae observed within mitochondria [39]
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The outer membrane (OM) contains many transporter proteins
tasked with the import and export of ions and proteins necessary to maintain
mitochondrial function [40]. This includes the Voltage Dependent Anion Channel
(VDAC) as well as Translocase of the Outer Membrane (TOM) Channel. The
inner membrane (IM) has many folds, termed cristae (Figure 1.2), and have
areas enriched with inner mitochondrial membrane proteins such as Complex I,
Complex III, Complex VI, ATP Synthase, the Adenosine Nucelotide Transporter
(ANT), the mitochondrial Calcium Uniporter (mCU), and the Hydrogen Calcium
and Sodium Calcium Exchangers (HCE and NaCE respectively), which will all
be discussed later due to their importance in mitochondrial bioenergetics and
dysfunction. It is these cristae which help to increase the surface area available
for mitochondrial respiration and are the site of electron transport and oxidative
phosphorylation (OXPHOS). The space between the outer and inner
mitochondrial membrane is called the inner mitochondrial membrane space and
the space enclosed by the inner membrane is termed the matrix. This matrix
space contains the enzymes involved in the Krebs Cycle and electron rich
compounds that feed into the electron transport chain.
When discussing mitochondrial bioenergetics and the history of
these important organelles, it is impossible to skip the Nobel Prize winning
work of Peter Mitchell. Keep in mind that within the late 50s, the idea of
substrate level phosphorylation and oxidative phosphorylation were both
proposed

as mechanisms leading to ATP production. Work from Edward

Charles (Bill) Slater, who was trained under Keilin (cytochrome work in the
mid-20s), proposed a
9

chemical nature for oxidative phosphorylation. In this “chemical-coupling
hypothesis”, redox reactions could occur between 2 molecules generating the
energy necessary to produce ATP [41-43]. However, this theory was lacking
information in that a high-energy intermediate necessary to produce the ATP
molecule from ADP + Pi was unknown. Then, in 1960s, two theories were
proposed, both of which proposed the flux of protons as the energy source
necessary for ATP synthesis. The first theory was proposed by Robert Joseph
Paton Williams who thought that the flux of protons occurred within the lipid
phase of the membrane [44]. The energetics allowed for a dehydration reaction
leading to condensation of ADP and Pi to ATP. Mitchell, on the other hand,
proposed a more physics based approach in which the lipid membrane acted as
a resistor and capacitor helping to separate charges in a manner similar to a
battery. This revolutionary theory was called the Chemiosmotic Hypothesis of
Oxidative Phosphorylation and will be discussed in further detail later in this
chapter [45-49].
At the time that researchers were trying to understand cellular respiration
and ATP production, Abraham E. Axelrod (1941) made an observation that
Calcium uptake increased oxygen consumption [50]. Although he proposed a
mechanism that was disproven, it is the first indication in the literature that
hinted

to

mitochondrial

mediated

Calcium

uptake.

Once

the

proper

mitochondrial isolation techniques were known, Siekewitz and Potter (1953) and
then Lehninger (1970) both confirmed that mitochondria were able to buffer
calcium in a manner that lead to increased oxygen consumption. To further
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expand upon this work, Vasington and Murphy (1961) showed that calcium
uptake was dependent on the respiratory chain and could be inhibited with the
use of 2,4 DNP and FCCP, two a well known membrane uncoupler [50]. As we
now know, this calcium uptake is dependent on the mitochondrial Calcium
Uniporters (mCU) that uses the membrane potential generated by the electron
transport chain in buffer cytosolic calcium.
In addition to ATP production and calcium cycling, mitochondria also
seem to have an important role in cell survival. Although early on the topic was
heavily debated as an in vitro artifact that had no pathophysiological relevance,
the mitochondrial permeability transition pore (mPTP) is now pretty well
accepted as a potential mechanism of cell death. In the early 50s and 60s, when
mitochondrial bioenergetics were being heavily studied, the ability for
mitochondrial swelling which was dependent on calcium, inhibited by Mg2+ and
ADP, was well documented [51-64]. Additionally, Mitchell even discussed this
phenomenon as a detriment to energy conservation during his proposal of his
Chemiosmotic Hypothesis. However, the mechanisms behind this swelling were
not explained fully until the late 1970s by Haworth and Hunter coined term
“permeability transition”. During their studies they described the reversible
opening of a proteinaceous pore in the inner mitochondrial membrane leading to
the possible flux of ions and solutes up to 1500kDa from the mitochondria to the
cytosol [65-68]. This theory was not well accepted until approximately 10 years
later when it was discovered that this pore could be inhibited by submicromolar
concentrations of cyclosporin A [69-75]. To date, the mPTP is thought to play a
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role in oncosis and apoptotic mediated cell death, all which will be discussed
later in detail due to their importance in cell death and, therefore, TBI.
Since their initial discovery in the 1840s, mitochondria are now known to
be an important and integral organelle in the cell. Their function, superficially, is
to mediate cellular respiration and cellular metabolism, in which the mitochondria
produce the energy rich compound, ATP, in order to provide an energetic
environment within the cell. However, due to work in the 50s and 60s, it is also
known that mitochondria have an important function in mediating calcium cycling,
which is dependent upon the function of the mitochondrial calcium uniporter. This
uniporter uses the potential in the inner membrane space to pump mitochondria
from the cytosol into the matrix. Lastly, mitochondria seem to have a very
important role in cell survival which can be mediated through the initiation of the
mitochondrial permeability transition pore.
Cellular Metabolism: Today’s Understanding
Cellular energetics is directly linked to ATP production which occurs
through cellular metabolism. Aerobic cellular metabolism can be broken down in
4 separate steps. The first step is the generation of compounds which can be
chemically recognized by metabolic proteins within the mitochondria and
transport into the mitochondria. Anaerobic metabolism does not include the use
of mitochondria generating ATP without the use of mitochondrial mediated
oxidative phosphorylation. The next step in aerobic phosphorylation is the Krebs
Cycle which is the site of production of the electron rich compounds NADH and
succinate. These electron rich compounds are then able to feed into the
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Electron Transport System/Chain (ETS), which is considered the third step of
cellular metabolism. Lastly, the fourth step which is the site of the ATP synthase,
producing an overwhelming majority of the ATP used by the cell. Each of these
steps and key players within these step will be discussed throughout the rest of
this chapter.
Glycolysis, Fatty Acid Oxidation and Urea Cycling
When the cell takes up metabolic compounds such as glucose, lactate,
fatty acids or various amino acids, it has to have a mechanism to break them
down into substrates that can be transported into the mitochondria and then
recognized by appropriate metabolic proteins. Three processes which are
important in generating substrates for mitochondria are Glycolysis, Fatty Acid
Oxidation and Urea Cycling. Glycolysis is a term generated from “glucose and
lysis” referring to the metabolic process of breaking down glucose, a 6-carbon
molecule, to pyruvate, a 3-carbon molecule. Pyruvate can be transported into the
mitochondria through either diffusion or the mitochondrial pyruvate carrier (MPC).
The existence of this transporter that has lead to some debate as to whether it is
truly necessary for pyruvate transport, which is a topic that will be discussed
some later in this chapter. However, whether through diffusion or MPC, pyruvate
will then translocate into the mitochondrial matrix where it will be further broken
down into acetyl co-A by pyruvate dehydrogenase (PDH). During the 10 step
glycolytic reactions that eventually produce pyruvate from glucose, 2 NADH
molecules are generated as well as 2 ATP molecules.
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There is a small subset of cells who produce the majority of their energy
through glycolysis. One of the most documented and heavily researcher topic
related to this are those cells who have undergone mutations, transforming them
into cancer cells. The scientific literature shows that cancer cells, which are
primarily glycolytic, and have little to no mitochondrial contribution to their
energetic profiles. These cells undergo a high rate of glycolysis followed by lactic
acid fermentation, having very little contributions from mitochondria. This is one
of many situations in which different cells types as well as different regions within
the body within the same cell type experience different metabolic profiles which
arise as variations in mitochondrial bioenergetics.
Another highly debated topic in terms of metabolic profiles of cells occur
specifically within the brain tissue. It has been well accepted that the brain is
considered immune privileged and is confined from the rest of the body by the
blood brain barrier. The vasculature within the cranial vault is able to provide
nutrients to the brain through either free diffusion of small lipid soluble molecules,
like oxygen and carbon dioxide, or through active transport. Glucose is thought to
reach cells within the brain through active transport by the GLUT1 or GLUT3
transporters. GLUT transporters are enriched in astrocytes allowing for glucose
to be favorably taken up by astrocytes and then broken down to pyruvate and
then potentially lactate. Although this topic is heavily debated, it is thought that
lactate is then transported from astrocytes to the neurons through the AstrocyteNeuron Lactate Shuttle, which was initially proposed by Pellerin and Magistretti in
the late 90s [76-80]. Once lactate is shuttled into neurons, it can undergo a
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dehydrogenation reaction with the assistance of lactate dehydrogenase (LDH)
producing pyruvate. Pyruvate can then enter the mitochondria as mentioned
previously. Differing opinions on this topic believe that neurons are able to take
up glucose through the GLUT 3 transporter leading to the initiation of glyocolysis
in a manner similar to what was described previously.
Additionally, mitochondria can use byproducts of fatty acid oxidation,
specifically fatty acetyl CoA, and urea cycle, specifically generating malate, as
substrates for ATP production. These metabolic processes are often overlooked
when energy to the brain is considered because traditionally glucose, and its
derivative lactate, are considered the main energy source. However, it has been
shown that up to 20% of the total brain’s energy is obtained through
mitochondrial mediated fatty acid oxidation [81] . Additionally, in diseased states,
such as following a traumatic brain injury, hypoglycemia is observed leaving cells
within the brain to adapt to changes in glucose.
Within this process a fatty acid molecule is shortened by 2 carbons for
every turn of the fatty oxidation cycle, producing 1 acetyl coA molecule, 1 NADH
molecule and 2 FADH2 molecules [82]. Additionally, the urea cycle has been
found to be an important mechanism in the brain for the removal of free nitrogen.
This cycle uses free ammonia in the body to feed into mitochondria at malate. In
addition, this urea cycle seems to be an important mechanism when considering
the generation of α-ketogluterate from glutamate, which is supported through
GDH activity, since ammonia is given off a byproduct in this reaction. This
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mechanism will be discussed later in this chapter, however is important to note
when thinking about the entirety of mitochondrial related metabolism.
Krebs Cycle
Once the appropriate substrates have reached the mitochondrial matrix,
the next important step in the metabolic process is initiation of the Krebs Cycle,
also called the Citric Acid Cycle and the Tricarboxylic Acid Cycle. This is
considered the central metabolic pathways for all aerobic organisms. The
process begins with a 2 carbon compound, specifically acetate in acetyl coA,
which is generated through the action of Pyruvate Dehydrogenase converting
pyruvate. From acetyl coA, 8 chemical reactions completely oxidize the carbons
to 2 carbon dioxide molecules, reducing NAD+ to NADH and generating
succinate in the process. These two compounds can then be used as substrates
within the electron transport chain, specifically at Complex I and Complex II
respectively. Additionally, as mentioned previously, malate can be generated
during amino acid oxidation feeding into the Krebs cycle during the 7th listed
reaction and glutamate is fed into the Krebs Cycle through the activity of GDH
producing α-ketoglurate (see below)
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Figure 1.3 The Krebs Cycle: The multi-step Krebs cycle is the site where
electron dense NADH and Succinate (FADH2) molecules are produced. These
substrates can then donate their elections to either Complex I or Complex II,
beginning a series of Redox which occur within the Electron Transport Chain.
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Within the Krebs cycle, any of the intermediate steps can be substituted
for molecules that are generated through processes outside of the Krebs Cycle.
One important reaction which seems to have some importance when
investigating the function of mitoNEET is the dehydrogenation reaction of
Glutamate to α-ketogluterate by Glutamate Dehydrogenase.
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Figure 1.4 Glutamate Dehydrogenase can produce α-ketogluterate:
Glutamate Dehydrogenase (GDH) is able to condense glutamate into αketogluterate while simultaneously generating an NADH molecule.
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Glutamate Dehydrogenase (GDH) is an enzyme found in all organisms,
however is specifically located in the mitochondria of humans. It catalyzes the
reversible oxidative deamination of glutamate and H2O producing αketogluterate and ammonia. α-Ketogluterate is then able to feed into the Krebs
Cycle leading to more NADH for the electron transport chain and ammonia is
then cleared from the mitochondria by the Urea Cycle. Interestingly, in lower
order organisms, GDH is modulated through transcriptional regulation however
in humans its modulation occurs through metabolites. Some important inhibitors
are GTP, NADH, ATP and Zn2+ and some important activators include ADP
and mitoNEET [83].
Traditionally speaking, PDH is thought to be the gatekeeper of
mitochondrial

respiration.

However,

with

compelling

evidence

showing

mitoNEET as a redox switch and showing mitoNEETs direct positive effects on
GDH activity, it proposes a theory in that GDH mediates mitochondrial
respiration through mitoNEET activity. This activity is inhibited in high oxidative
states, such as during calcium cycling, leaded to decreased substrates feeding
into the electron transport chain and therefore inhibiting state III mediated
respiration.
Electron Transport Chain
The electron transport chain consists of a series of proteins that are
located within the inner mitochondrial membrane, with the exception of complex
II that is within the mitochondrial matrix. As mentioned previous, mitochondria
have invaginations within their inner mitochondrial membrane which is called
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cristae. Within these cristae there are the protein complexes that comprise the
electron transport chain (ETC). The components of the ETC include complex I,
II, III, IV as well as the mobile carriers, coenzyme Q10 and cytochrome C.
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Figure 1.5 The Electron Transport System: The electron transport chain is
the site for an overwhelming high production rate of ATP with respects to
any other location in the cell. The ETC/ETS cycles through a series of redox
reactions. This results in protons being pumped to the inner membrane
space which generates a proton-motive force that is harnessed by Complex
V to produce ATP.
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As electrons are transferred through the electron transport chain, the
redox potential of those electrons increase from -400mV, when they are
associated with NADH, to 800mV which is where they terminate the process,
associating with free oxygen. As the redox potential increases, the Gibbs Free
energy decreases in the following manner:
−Δ𝐺 = 𝑛𝐹∆𝐸
Where n is the number of electrons being transferred, F is defined by
Faraday’s Constant and ΔE is defined by:
∆𝐸 = ∆𝐸° +

𝑅𝑇
𝐴12 3 𝐵567 3
ln
𝑛𝐹
𝐴567 3 𝐵12 3

For the following redox chemical reaction.
𝐴567 + 𝐵12 → 𝐴12 + 𝐵567
Within this equation, ΔE° = ΔE°(cathode) - ΔE°(anode)
Within this process, the complexes act as an energy-conversion devices,
using the free-energy to pump protons from the matrix into the inner membrane
space.
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Figure 1.6 ETS Energy Changes: This diagram provides the redox potential and
the free energy changes that occur as electrons are cycled through the electron
transport chain and protons are pumped into the inner membrane space.
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Complex I
As mentioned previously, once NADH is produced within the mitochondria
it is able to diffuse to the site of the Electron Transport Chain (ETC), specifically
to Complex I. Complex I acts as a “gatekeeper” or “entry point” of the ETC
therefore serving as a direct link between glycolysis, the Krebs Cycle, fatty acid
oxidation, GDH activity and the electron transport chain. It is often called NADHUbiquinone Oxidoreductase, or NADH dehydrogenase, since it mediated the
oxidation of NADH oxidation and the reduction of Ubiquinone. It is the largest
catalytic complex within the electron transport chain having of mix of 45 nuclear
and mtDNA generated subunits. Within this ~1000kDa structure are 7, out of the
45, subunits that are encoded by the mitochondrial DNA (mtDNA). Its molecular
mass is little under 1000kDa and has a structure similar to a boot. The “foot” of
this “boot” is hydrophobic and integrated into the inner mitochondrial membrane
[84, 85]. This is the region which one would find the mtDNA encoded subunits.
The “ankle” of this “boot” is hydrophilic and extends into the mitochondrial matrix.
The exact coupling mechanism and structure of this protein is unknown
however has been proposed by many scientists including Efremov [86]. Within
the hydrophilic “ankle” region is the primary electron acceptor flavin
mononucleotide (FMN) which is the initial redox site for the oxidation of NADH to
NAD+. The electrons are then transferred strategically through seven conserved
iron-sulfur (Fe-S) clusters, reaching the N2 cluster which is where the electrons
are thought to then be transferred to the ubquinone binding site (Q-site). The
hydrophilic region is also called NADH-ferricyanide reductase due to this exact

25

process. This Q-site is located at the interface of the membranous domain. The
atomic structure of the hydrophobic region of complex I is unknown however
within this region there are 3 well defined subunits (NuoL/Nqo12, NuoM/Ngio13,
NuoN/Nqo14) which are homologous to one another and the Na+ or K+/H+
antiporter. It is thought that this is the site where proton translocation occurs
however this too is debated. A scheme is provided below to better explain the
previous process.
The overall reaction that occurs at complex I is:
NADH + CoQ + 5H+ à NAD+ CoQH2 + 4H+
In which NADH is converted to NAD+ by accepting an electron into the
Fe-S center of the protein and then transferring them to coenzyme Q10 [87-91].
Historically, there are three well known inhibitors of Complex I that have
been found to inhibit the reduction of ubiquinone. These inhibitors have been
categorized into 2 to 3 different types depending on your source. This
classification is dependent on kinetic studies including Class I/A-type, Class II/Ctype and C-type. Class I/A-type is represented by an antibiotic called piercidin A,
Class II/B-type is represented by a fish poison called rotenone, and C-type is
represented capsaicin [92, 93]. These inhibitors all seem to bind within the same
relative region of the complex however the exact mechanism of action are
seemingly different. Work from Fato found that the Class I and Class II,
categorized into Class A, inhibitors have been shown to increase reactive
oxygen species where the Class B, referred to as Class III/C-Type in other
locations, leads to decreased ROS production. The mechanism of actions of
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these inhibitors are important to know in order to A) further understand the exact
structure of Complex I and B) to understand how mutations and toxins which
effect the structure and function can lead to specific diseases.
It is seemingly important to provide further clarification at this point. The
use of mitochondrial inhibitors should not be confused with mitochondrial
uncouplers. In the literature, the term uncoupler seems to be very freely. When
using uncouplers, the redox reactions that occur within the electron transport
chain persist, however the uncoupler in question depletes the membrane
potential leading to no functionality at the ATP synthase, and therefore no ATP
production. Specifically, uncouplers are able to unlink the redox reactions
(electron flow) within the ETC from the phosphorylation of ADP molecules at
the site of the ATP synthase. During the use of uncouplers, the redox reactions
within the ETC are generally running at maximum capacity in order to
regenerate the concentration of hydrogen molecules within the inner membrane
space. However, as these protons are pumped into this inner membrane space,
they are immediately translocated back into the matrix, leading to no overall
change in the membrane potential and no protonmotive force to run allow ATP
synthase to function. On the contrary, when using mitochondrial inhibitors, this is
a term that is specific for compounds that actually interact with proteins to stop
their function, leading to a halt in the redox reactions at the ETC. For instance,
rotenone is a commonly used Complex I inhibitor which will be discussed later in
this document. Rotenone interacts with Complex I, inhibiting the flow of electros
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through the complex. This leads to no electrons entering the ETC and therefore,
no functionality of the ETC.
ROS production is seemingly a hallmark of Complex I activity. It has been
well documented that Complex I is one of the main sites of the production of
reactive oxygen species for the ETC [94]. Within this complex, electrons are at
their highest relative potential compared to any other site within the ETC. It is
thought that this high potential leads to increased electron leak within the
complex. As electrons leak out of the complex, they are able to bind to free O2
generating superoxide anions. These anions can be neutralized by antioxidant
defense mechanisms such as the mnSOD (manganese superoxide dismutase)
however at times they are able to evade this mechanism and damage nearby
proteins. The exact site of this electron leak is unknown however strong
evidence has been proposed by Fato that it occurs at the N2 cluster mentioned
previously, which is the site immediately before the electron is transferred to
ubiquinone. However, contradicting evidence has also been proposed
implicating ubisemiquinone, FMN, and the iron-sulfur cluster N1a as contributor
to ROS.
In addition to the damage that ROS can do to nearby proteins, mtDNA
can also become damaged due to the havoc wrecked by ROS production. It is
thought that throughout the life of an organism somatic mutations to
mitochondrial DNA accumulate due to years of ROS, as well as RNS (reactive
nitrogen species), mediated damage. This DNA damage leads to the production
of damages proteins. Since Complex I has 7 subunits encoded by the
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mitochondrial genome, it is thought that this protein takes the largest hit, leading
to increased electron slippage. This theory is terms the “Mitochondrial Theory Of
Aging” which will be discussed in more detail in Chapter 2.
Complex II
Complex II (Succinate:Ubiquinone Oxidoreductase), also referred to as
Succinate Dehydrogenase), utilizes the conversion of succinate to fumarate to
generate FADH2 from the FAD (flavin-adenine dinucleotide) coenzyme. This is
the only Complex within the ETC that is also an integral part of the Krebs cycle,
being utilized in the 6th chemical reaction where succinate is converted to
fumarate [95].. This complex has a covalently linked FAD molecule within it.
Once in contact with Succinate, electrons are donated to the FAD molecule,
generating FADH2. From the production of FADH2, electrons are then
transferred sequentially between 3 different Fe-S groups until reaching the
membranous location of Complex II. At this point the electron is passed to heme
b group (CybL-CybS) and then transferred to ubiquinone. This is the only
complex within the ETC that does not contribute to the membrane potential
discussed previously since there is no translocation of protons from the matrix to
the IMS, making it a less energetically favored process compared to Complex I.
The overall reaction generated by this complex is
Succinate + Q ⇔ Fumarate + QH2
Where Q is ubiquinone and QH2 is ubiquinol, the reduced form of
ubiquinone.

29

Complex III
Complex I and II transfer their electrons to Ubiquinone (Coenzyme Q10)
located within the IM. Complex III is the next player in this process which
oxidizes

Ubiquinol

producing

Ubiquinone

(Ubiquinol-Cytochrome-C

Oxidoreductase) eventually reducing Cytochrome C via the protonmotive Qcycle. This complex is much smaller than Complex I containing only 11 subunits,
3 of which are respiration subunits (cytochrome B, cytochrome C1 and Reiske
protein which is an Fe-S cluster), 2 which are core proteins and 6 are lowmolecular weight supporting proteins.
2 electrons are transferred to Complex III when Ubiquinol is oxidized to
Ubiquinone. One of these electrons is transferred onto the 2Fe-2S group of the
Rieske center. Rieske proteins are a specific iron-sulfur proteins found within
cytochrome bc1 and cytochrome b6f complexes. From this center, electrons are
able to transfer to the heme group of Cytochrome C1 and then picked up by
cytochrome c and diffuses to Complex IV. The other of the 2 electrons is
transferred onto a heme group in cytochrome b before being transferred to a
ubiquinone molecule. This leaves ubiquinone in a partially reduced form
generating a semi-ubiquinol radical. Then, a second ubiquinol molecule diffuses
to complex III donating its electrons in a similar manner. Now, the semiubiquinol molecule can gain a second electron resulting in the production of
another ubiquinol and the process repeats itself. During this process, 2 ubiquinol
molecules are used to translocate 4 protons from the mitochondrial matrix to the
inner membrane space.
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The overall reaction that occurs at the site of complex III is
QH2 + 2Cyt C3 + 2H+ ⇔ Q + 2Cyt C2 + 4H+
As mentioned previously, Complex I contributes to a large amount of the
electron leak that occurs within ETC. However, Complex III also contributes to
this electron leak. It is thought that approximately 1 to 2% of the O2 used within
the mitochondria is due to this electron leak [2, 96]. It has been discovered that
the within the center of Complex III is a high reduction potential chain called Q0
which contains the Rieske protein (Fe-S cluster). This is the site in which the
majority of electron slippage is thought to occur.
Complex IV
As the last step in the ETC, Cytochrome C transports its electrons to
Complex IV (Cytochrome-C Oxidase). Because of its position within the ETC,
Complex IV is often considered a major regulator of Oxidative Phosphorylation. It
is made up for 13 subunits which is contributed to by both nuclear (10 proteins)
and mitochondrial (3 proteins) encoded proteins [97]. It is thought that the
nuclear encoded proteins primarily regulate oxygen consumption and proton
translocation and the mitochondrial encoded proteins are the catalytic sites.
There are 4 redox-active centered within Complex IV. Listed in the order
of function, CuA, heme a (Fea), heme a3 (Fea3) and CuB. CuA is initially reduced
by cytochrome c. From here the electron travels to Fea and then enters the
“catalytic” site of the complex (where Fea3 and CuB are located) where free
oxygen is reduced eventually leading to the production of H2O. During this
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process 2 protons are pumped from the mitochondrial matrix to the inner
membrane space.
The overall chemical reaction for Complex IV is
4 Fe2+-cytochrome c + 8 H+ + O2 → 4 Fe3+-cytochrome c + 2 H2O + 4 H+
In which electrons are given off by a reduced form of cytochrome c,
translocate through the complex until they reduces free oxygen and eventually
produces H2O. During this process, H+ ions are pumped into the inner
mitochondrial space helping to contribute to the membrane potential, which will
be used by Complex V/ATP Synthase to generate ATP molecules.
ATP Synthase
Following the contribution of an NADH molecule and consequently 2
electrons being donated to the ETC, 10 protons will be translocated into the IMS.
As we know, the ETS is continuously cycling and therefore protons are
continuously being pumped out of the matrix. As the concentration of protons
within the IMS increases, a multi-component proton-motive force is generated
having both a differential pH and an electrochemical gradient leading to a
membrane potential (ΔΨ) [98]. This high energy environment is utilized by
Complex V (ATP Synthase) to facilitate the phosphorylation of ADP into ATP.
Complex V, like the other Oxidative Phosphorylation Complexes, is
located, partially, within the inner mitochondrial membrane. It has multiple
subunits which are contributed to by both nuclear and mitochondrial genes. In
addition to having multiple subunits, this complex also has multiple domains
including the Fo domain, the F1 domain and the stalk/accessory domain. The Fo

32

domain is the hydrophobic domain located within the membrane. This domain is
often referred to as the “motor” of the complex. It has 1a, 2b and 12c (debated
10-15c) subunits [99]. The c subunits are aligned in a ring shape forming the
proton channel that funnels the protons from the IMS to the F1 domain. These c
subunits are thought to interact directly with the F1 domain to regulate proton
flow and consequently ATP production [99].
As mentioned previously, the Fo domain is often thought to be the motor
of the complex. When the c-ring rotates, being “pushed” by the high-energy
proton-motive force mentioned previously, it causes movement of the γ subunit
within the F1 domain, which is attached to the c-ring. The ε subunit causes a
confirmation change in the α and β subunit within the F1 domain. As these
confirmation changes occur, it opens the α and β subunit to the matrix allowing
the diffusion of ADP and Pi into the catalytic region of these subunits. Then, the γ
subunit rotates again causing the condensation reaction for ADP + Pi to ATP
generation. The next rotation of the γ subunit causes a third confirmation change
to the α and β subunit which opens the site to the matrix again. This allows ATP
to flow out and ADP + Pi to diffuse in, repeating the process [100].
In addition to the Fo and F1 subunit, there is also an accessory/shaft
domain which includes an Oligomycin Sensitivity Conferring Protein (OSCP)
subunit. This is the site where a bacterial antibiotic called oligomycin interacts.
When oligomycin binds to this OSCP subunit, it inhibits the rotation within the Fo
domain and consequently blocks the catalytic site of the F1 subunit leading to a
complete inhibition of the ATP Synthase [101].
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Figure 1.7 ATP Synthase: A diagram of Complex V/ATP Synthase including
the subunits where were specified previous within the text.
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Chemiosmotic Coupling
Properly defined, the principal of Chemiosmotic Coupling is based upon
the physical chemical property called Chemiosmosis. Chemiosmosis is the
physical movement of ions from a highly concentrated region to a lower
concentration region when these regions are separated by a selectively
permeable membrane. This process requires the use of a transport protein since
the ions in question are not permeable across the selectively permeable
membrane. This principle is analogous to the principles of osmosis however as
opposed to the flow of water, chemiosmosis concentrates on the flow of ions.
Within the mitochondria, these ions are protons. In 1961, Dr. Peter Mitchell was
awarded a Nobel Prize for defining this process which is harnessed to make ATP
within mitochondria and provides a physical chemical understanding to the ETS.
Within mitochondria, Complex I, III, and IV use the energy rendered by
local redox reaction to pump hydrogens into the IMS. These protons within the
IMS are not permeable through the inner membrane, which is the selective
permeable membrane in question. The ATP Synthase/Complex V then uses the
principles of Chemiosmosis to provide the energetics necessary to generate the
high energy ATP molecules.
ROS Production
Although OXPHOS is an amazing process, it does have the propensity to
create toxic byproducts. Because of this, mitochondria are not only known as
the cell’s power plant but they are also known as one of the cell’s major supplier
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of Reactive Oxide Species (ROS) and Reactive Nitrogen Species (RNS). During
OXPHOS, complex IV will release an electron to molecular oxygen (O2) allowing
for the eventual formation of H2O. However, electrons “slippage” can also occur.
This occurs as a result of inefficiencies within primarly Complex I and III,
however slippage also occurs at Complex IV. Once an electron slips, or is
released, from the ETC, it can reduce O2 and/or react with proteins, nucleic
acids and fatty acids within the mitochondria and mitochondrial membrane
leading to damage. This process is often referred to as metabolic mediated
oxidative damage.
Following slippage of an electron from the ETC, mitochondrial
manganese superoxide dismutase (MnSOD, SOD2) which is a mitochondrial
located metalloenyzme that is a crucial for the dismutation of this highly reactive
O2•− into H2O2, can neutralize any reactive O2•− formed. This protein is located
within the mitochondrial matrix, within the vicinity of the ETC. However, H2O2 is
also a strong oxidizing agent and therefore needs to be further neutralized.
Glutathione peroxidase, which is also located within the mitochondria, is then
used to convert H2O2 into neutral H2O [102, 103].
The mechanisms used to neutralize of these toxic byproducts are very
efficient however even with them in place the cells within the brain still seem to
be more vulnerable to oxidative stress compared to other tissues. This has been
attributed to the fact that the brain is a high energy organ that consumes
approximately 20% of the body’s total oxygen and has naturally lower levels of
endogenous antioxidant activity relative to other tissue [104-106]. Neurons have
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high energy demands compared to other cell types. The Na+/K+ ATPase pumps
located within their cellular membrane function to maintain the membrane
potential necessary for action potentials to be generated. It is estimated that 1/3
of the entire body’s ATP production in 1 day is used by these pumps [107]. Due
to the fact that neurons primarily use mitochondrial oxidative phosphorylation to
generate their ATP pools, they produce more metabolic mediated oxidative
stress which can be detrimental to the cell over time.
Calcium Cycling
In addition to producing 95% of the cell’s energy currency, ATP, and being
a major source of oxidative stress, mitochondria also play an integral role in the
buffering of cytosolic calcium. This is important since calcium is a potent
intracellular signaling molecule which has beneficial and detrimental roles in
neurons. In the brain during normal cellular interactions, neurons become
activated following the binding of various neurotransmitters to their respective
metabotropic and/or inotropic receptors. One interesting neurotransmitter that
has been implicated in the calcium signaling pathway and has an important role
in the secondary injury cascade of TBI is glutamate. Glutamate binds many
receptors but one of importance when discussing calcium cycling is the α-amino3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor, also known as the AMPA
receptor. Voltage dependent Na+ channels within these same synaptic densities
can also activated by glutamate. Once glutamate is bound, these ionotropic
receptors move to an open confirmation leading to the influx of Na+ causing a
local depolarization. This local depolarization leads to the displacement of the
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Mg2+ blockage in the N-methyl-D-aspartate receptor, NMDA receptor. Once
removed, the NMDA receptor has a higher probability of being in an “open”
confirmation allowing Calcium to enter the neuron.
As the NMDA receptors remain in an open confirmation, Calcium will
continue to enter the neuron. At lower concentrations, this Calcium has been
shown to regulate neurotransmitter release within the synaptic cleft. Also, as
transient increases in cytosolic Calcium level occur, mitochondria sink Calcium in
an electrogenic fashion, removing the ions from the cytosol. These increased
Calcium levels within the mitochondria have been shown to directly regulate the
Krebs cycle through activation of pyruvate dehydrogenase, PDH, NAD+dependent isocitrate dehydrogenase, ICDH and α-ketoglutarate dehydrogenase
complex, KGDHC. Activation of these various metabolic proteins all leads to
increased NADH production, which can, in turn, generate increased ATP
production by the ETC. Calcium mediated activation has also been shown to
increase Complex V (ATP Synthase) activity resulting in increased ATP
synthesis as well [108, 109].
In addition to the direct effects of Calcium within the mitochondria, these
ions also have indirect effects which is equally as important to mitochondrial
function and therefore cellular metabolism. As mentioned previously, the ETC
generates a negative membrane potential, ΔΨ, within the mitochondria. Calcium
uniporters, located in the inner mitochondrial membrane, use this ΔΨ generated
by the ETC to pump calcium ions down their electrochemical gradient into the
mitochondrial matrix. As the calcium uniporters continue to translocate calcium
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into the matrix, the ΔΨ diminishes leading to further activation of the ETC in an
attempt to restore the depleted potential. This process provides an intimate
relationship between mitochondrial bioenergetics, calcium homeostasis and ATP
production. This same mechanism can eventually lead to mitochondrial
dysfunction when calcium levels become too high. In many diseased state, such
as following an injury to the CNS, calcium dysregulation is often observed. This
can lead to electron slippage at the site of the ETC and pathogenic decreases in
mitochondrial membrane potential. In the process, oxidative stress increases
which can inititate the formation of the mitochondrial permeability transition pore,
mPTP.
Mitochondrial Permeability Transition Pore
Healthy mitochondria generally maintain a Nernstian membrane potential
of around 180mV. As mitochondrial matrix Calcium concentrations, oxidative
stress and damage to ETC proteins increases, this ΔΨ can become depleted.
Once around ~100-120mV, the ETC will begin to slow down, stop and potentially
start running backwards. Once this occurs, ATP production will decrease and if
the ETC begins to run backwards, then ATP will be consumed by the ATP
synthase\Complex V. Not only will this lead to decreased ATP stores but
generates ROS and RNS [110]. The increase in ROS and RNS can then lead to
increased oxidative damage within the mitochondria. Mitochondrial dysfunction is
further exacerbated as the damage to lipid, protein and nucleic acid modifications
continues. Eventually, the redox potential within the mitochondria changes and
crucial mitochondrial proteins like adenine nucleotide translocator (ANT) undergo
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oxidative modifications. This occurs specifically as a thiol oxidation on ANT
resulting in a conformational change that promotes cyclophilin D (cypD) binding.
Once ANT, an inner membrane mitochondrial protein, is bound to cypD, an
appropriate conformational change occurs in order to promote ANT, cypD, and
many other proteins within the complex to bind with voltage-dependent anion
channel, VDAC [111-113]. VDAC is an outer membrane mitochondrial protein
that once bound to this inner mitochondrial membrane protein complex, including
Cyclophilin D, ANT, and many other proteins, forms the mitochondrial
permeability transition pore, mPTP. The formation of the mPTP is a heavily
debated topic with many models proposed. This specific mPTP description is the
classic model which provides a good foundation for some of the therapeutic
approaches which will be discussed further in Chapter 2.
Whatever model you prefer for the mPTP formation, once formed the pore
exposes the inner mitochondrial matrix to the cytosol, allowing the mitochondria
to release apoptotic initiating factors like Cytochrome C, SMAC/diablo and AIF
which all promote cell death. Additionally, mitochondria can also initiate another
route of cell death called necrosis. This occurs as a result of ion concentration
difference, like chlorine, across the mitochondria membrane. These ionic
concentration differences allow water to freely diffuse cross the mitochondria
membrane as a result of osmosis. As this perpetuates, swelling of the inner
membrane occurs due to osmotic pressure, ATP production decreases due to
dysfunction within the ETC, the mitochondrial membrane potential decreases and
oxidative stress to increases. This causes a complete destruction of the
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mitochondria as a result of the swelling of the inner mitochondrial membrane.
Eventually these mitochondria will burst leading to the initiation of cell death.
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Figure 1.8 The mechanisms of mitochondrial mediated cell death:
Mitochondrial mediated methods to cellular death. This figure was adapted from
[108]
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Redox Sensitive Switch in Mitochondria
In terms of history, to date, research related to mitochondrial homeostasis
or dysfunction in various disease states is flourishing. Following the generation
of a specific group of PPAR ligands called thiazolidinediones, TZDs or glitazone,
which will be discussed at the end of chapter 3 and within chapter 4, a novel
mitochondrial membrane protein was discovered (2004). This protein was found
to bind to a specific TZD which is FDA approved for type 2 diabetes called
pioglitazone. This novel mitochondrial membrane protein was termed mitoNEET
due to its CDGSH-type zinc finger domain which actually binds iron, as opposed
to zinc. mitoNEET has been labeled as an outer mitochondrial membrane
protein however from the same report that published the work, it was found to
have a localization within the inner mitochondrial membrane as well.
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Figure 1.9 Location of mitoNEET is not just the outer mitochondrial
membrane: Work from Wiley showing the mitoNEET is located within the outer
membrane however can also be found in the inner mitochondrial membrane
[114]. This figure was edited from [76] showing the presence of mitoNEET within
inner membrane fractions.
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Further supporting the notion that mitoNEET can also be localized within
the inner mitochondrial membrane is work from Roberts et. al. at Eastern Illinois
University. They found that mitoNEET is able to bind to Glutamate
Dehydrogenase I (GDHI), which is a protein located in the mitochondrial matrix,
and that this interaction leads to increased GDHI activity [83]. Additionally, within
the work, mitoNEET was found to form homodimers proposing a mechanism is
that mitoNEET binding GDHI leads to increased GDHI activity however in
oxidized states mitoNEET can homodimerize leading to decreased GDHI activity
[83]. Recent work from Landry also found that once oxidized, glutathione
reductase is able to reduce mitoNEET back to its original structure, in theory
rendering it active again [115].
As mentioned previously, mitoNEET will be discussed further in the
following chapters, however this protein has become of great interest to
researchers who investigate redox shift within mitochondria. Due to its structure,
which contained Fe-S clusters, this protein is structured perfectly to react to
changes in redox state. Additionally, mitoNEET has also been shown to mediate
mitochondrial respiration, allowing for the hypothesis that this protein would be
able to sense possible harmful changes in redox and inhibit respiration to avoid
damage to inter-mitochondrial proteins. This is a novel idea which will be
expanded upon later in this document.
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Methods Used to Measure Mitochondrial Respiration
Prior to 1944, when Albert Claude published the first recipe for the
appropriate buffers to isolate mitochondria, the field of mitochondrial studies were
heavily based on microscopic studies. Upon the isolation of healthy, viable,
respiring, well coupled mitochondria, many more studies could be done. Some of
these initial methodologies are still used till this day.
As mentioned previously, mitochondrial oxidative phosphorylation couples
the use of oxygen, which is reduced to water at Complex IV, to the
phosphorylation of ADP, which occurs at Complex V. Therefore, the rate at which
oxygen is consumed by mitochondria will give insight into the bioenergetics,
which is specific for the substrate given to allow the mitochondria to respire.

Clark Electrode/Oxytherm
In order to measure the amount of oxygen used by mitochondria, a
method for measuring small changes in oxygen within a liquid had to be
discovered. This was done by Leland Clark in 1953. Know as the “Father of
Biosensors”, Dr. Clark used a Ag/AgCl electrode and a Pt cathode separated by
a KCl electrolyte to measure oxygen within a sample. The principles of this
design were adapted in 1972 by Hansatech Limited, a electronic company,
located out of King’s Lynn in Northern Europe. Within this device, a potentiating
voltage is applied across two electrodes. This causes the platinum to become
negative and the silver to become positive, generating a cathode and anode
respectively. These surfaces are then covered with a thin layer of KCl solution
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and an oxygen permeable membrane. As oxygen diffuses through the
membrane, it is reduced by the platinum allowing for a current to flow through the
KCl solution. The silver is then oxidized and silver chloride is deposited on the
anode. Figure 1.10 shows images of an oxytherm electrode being prepared and
a diagram to indicate the importance of each component within the electrode.
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Figure 1.10 Clark Electrode: Building the electrode is an important step
when using the oxytherm. The electrode has a platinum cathode and silver
anode within the device. A drop of KCl buffer is added to the top of the
cathode and anode and then a piece of cigarette paper is added to the top of
the electrode, which should have contact with the cathode and anode, in
order to build the appropriate KCl bridge. A piece of Oxygen Permeable
Membrane is then added to the top of the electrode and secured in place
with a rubber o-ring.
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The chemical reaction that occurs are each cell is as follows:
At the platinum cathode:
O: + H: O + 2e> → H: O: + 2OH >
H: O: + 2e> → 2OH >

At the silver anode:
4Ag → 4Ag B + 4e>
4Ag B + 4Cl> → 4AgCl
As one may notice, this leave 4AgCl as an end product. This does occur
and leads to accumulation on the anode which has to be removed overtime.
[116]
Once the electrode is “built”, it is attached to a cord and the corded
electrode is secured within the back of the Oxytherm Electrode Control Unit. The
signal from the electrode then travels through the cord to the control unit where it
is converted into a digital readout that is then read by the computer.
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Figure 1.11 The Hansatech Oxytherm: The Oxytherm which is where the
electrode from figure 1.10 is secured. Mitochondria with respiration buffer
are placed within the chamber and the electrode is placed on the underside
of the chamber. This allows the electrode to measure the change in oxygen
content within the mitochondrial slurry located within the chamber.
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Seahorse
Another novel device that has gained increasing popularity over the last
few years as a tool for measuring mitochondrial bioenergetics is the Seahorse
Bioscience Flux Analyzer. This device uses an 8, 24 or 96 well microplate
allowing the researcher the ability to measure multiple sample at one time.
Similar to the Oxytherm, this device measures oxygen within a slurry however
the measurement techniques are different and therefore allow for the
measurement of the proton concentration as well. The Seahorse disposable
assay kit has two parts. The first part is the sample cell culture microplate which
is where your 5-10ug of mitochondrial protein are placed in approximately 500uL
of respiration buffer (recipe provided in the methods section). The second portion
of the cartridge is called the solid state biosensor cartridge. This cartridge has
four injection ports and two biosensor sleeves per well. The four injection ports
allow for the injection of 4 different mitochondrial substrates or drugs per well for
your study. The biosensor sleeves are strategically placed in the center of the
four ports and are the site at which oxygen, and proton, levels within the
mitochondrial sample are measured.
At the base of each sleeve are patented polymer embedded fluorophores.
The oxygen biosensor quenches in the presence of oxygen and the other
flurophore is sensitive to protons. As the substrates or drugs from the ports are
injected, the mitochondria within the sample begin to respire respectively. This
leads to a signal which is read by optic fibers within the actual seahorse machine.
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Figure 1.12 Seahorse Diagram: Representative figures of the Seahorse
Bioscience Flux Analyzer with the Biosensor Cartridge, microplate, polymer
fluorphores and fiber optics (within the Seahorse) where the signal is read.
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Pros and Cons of Both Methods
Although both methods are efficient at measuring mitochondrial
bioenergetics, depending on the experiment that one is running, one method may
be superior to the other.
Oxytherm
Pros
1. Allows for intricate studies where drug or substrate
concentrations can easily be adjusted throughout the
experiment.
2. No Limit on the number of substrates added.
Cons
1. Requires 50-100ug of mitochondrial protein.
2. Can only run one sample per Oxytherm device. *Multiple
Oxytherm devices can be run in serial order
3. Takes approximately 15 minutes per sample
Seahorse:
Pros
1. Can run 8, 24 or 96 samples at one time.
2. Only requires 5-10ug of mitochondrial protein.
3. Takes approximately 37 minutes to run each plate, see table
in methods section for specific details.
Cons
1. Only has 4 injection ports
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2. Cannot vary any of the experiment once the plate is placed
in the Seahorse
3. If too much mitochondria or substrate is added during the
loading process of the plate, the reliability of the OCRs are
lost. This requires further calculations after the experiment is
run.

Copyright © Heather Marie Yonutas 2016
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CHAPTER 2: MITOCHONDRIAL FUNCTION VARIES WITH AGE AND TISSUE
TYPE
As discussed in Chapter 1, mitochondria are extremely important for
normal cellular metabolism, ATP production, calcium cycling and the mediation of
cell death. These functions lead to overall cellular homeostasis and, therefore,
proper cellular function. When observing mitochondrial function however, it is
important to consider the cellular environment of those specific mitochondria. It
has been shown that mitochondria found in one tissue type may not act the same
as mitochondria in another tissue type, such as spinal cord mitochondria
compared to cortical tissue mitochondria or liver mitochondria. Additionally, even
mitochondria within the same cell type, such as synaptic versus non-synaptic
regions of a neuron, seem to exhibit different bioenergetics. To further confound
this topic, in many diseased states mitochondrial dysfunction has been observed.
Aging is one culprit which can lead to increased cellular damage resulting in
cellular dysfunction. Throughout this chapter, the effects of aging within brain
derived mitochondria and how these changes become more apparent within
specific tissue types will be discussed. Additionally, from the research it seems
as if TBI mediated mitochondrial dysfunction may mimic accelerated forms of the
mitochondrial theory of aging. This is important because it proposes a
therapeutic use of the pharmacological agents used to target the cellular and
mitochondrial dysfunction related to pathological aging states to assist with TBI
related dysfunction as well.
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Age Related Changes in the Brain
Throughout a person’s life, their brain is constantly undergoing structural
changes. Imaging studies in humans have repeatedly shown that aged brains
have decreased gray and white matter and enlarged ventricles [117-119].
However, surprisingly, these age related changes in brain volume do not seem to
be due to a loss of neurons but are seemingly the result of shrinking neurons,
reduced synaptic spines, decreases in synapses and changes in myelination
[119-128]. As these structural changes in the brain occur, functional changes
also ensue. With age related structural changes, the functional changes
observed are generally thought to result in a deficit. For instance, reduced
cognitive abilities, such as processing speed, attention, executive functions, and
episodic memory, are all commonly seen in healthy aging [129-134]. In a large
population

these

age

related

functional

deficits

can

progress

into

a

neurodegenerative disease states like Alzheimer’s Disease (AD).
With age related structural and functional changes, increasing evidence
has provided strong support that specific cellular changes occur in brain as well
[135-138]. The cellular changes observed are thought to be linked to the
anatomical and functional changes that occur in the aging brain. Some of the
most common cellular changes observed with age are the oxidative damage of
lipids, proteins, RNA and DNA. In the 1950’s, a researcher at the University of
Berkley, Denham Harman, proposed a compelling mechanistic link between the
functional and cellular changes observed with aging. At the time, Dr. Harman had
conducted years of radiation experiments, which is known to induce free radicals
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and therefore cause damage. During these studies he also observed metabolic
changes that were similar to what was seen in aging. With these findings he
hypothesized that with aging free radical damage accumulated, similar to what
was seen with radiation treatment. The years of accumulating free radicals
eventually resulted in oxidative damage to intracellular components leading to
cellular dysfunction and changes in metabolism. This theory became the
foundation for the Free-Radical Theory of Aging (FRTA) [139] and provides a
mechanistic link between oxidative damage, cellular dysfunction, changes in
metabolism and age. To further support this theory, studies of human autopsy
tissue show higher levels of oxidative damage to nucleic acids [140-142],
proteins [141, 143-146] and lipids [142, 146, 147] in aged brain as compared to
young brain and changes in brain metabolism has been linked to various age
related disease [148-150].
As mechanistic studies into the sources of oxidative stress progressed,
Chance et al showed that the mitochondrial electron transport chain was a
source for the production of reactive H2O2 which is a strong oxidizing agent,
which was mentioned earlier [151]. Further expanding upon these findings, it was
also found that the H2O2 produced was a product of MnSOD converting O2•- to
H2O2 [2, 152-154]. As mentioned previously, SOD2 is now knows as a
mitochondrial located metalloenyzme that is a crucial for the dismutation of highly
reactive O2•- into H2O2 and O2 [155]. This was an important finding for two
reasons: One: It proved mitochondria were an important site for ROS production.
Two: It proved, for the first time, that oxidative stress was linked directly to
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metabolism. As mentioned previously, in normal metabolic processes, ROS and
RNS are produced. [156-159]. In a healthy system, after production, these
reactive

species

are

immediately

neutralized,

avoiding

deleterious

consequences. However, if not neutralized, they can diffuse away from the site of
production and damage proteins, lipids, DNA or RNA [156].
With the production of ROS and RNS being understood as a byproduct of
OXPHOS, Harman expanded upon FRTA to acknowledge mitochondria as the
major source of oxidative stress within a cell. He modified FRTA to the
mitochondrial free radical theory of aging (MFRTA) [139, 160]. Linking age
related functional deficits to the function of an organelle became an important
turning point in the study of aging. As the “powerhouse” of the cell, mitochondria
are extremely important organelles for normal cellular homeostasis [7].
Interestingly, within anaerobic cells and tissues, 90% of oxygen consumed is
used by mitochondria. Mitochondria primarily use this oxygen for the production
of ATP during oxidative phosphorylation within the electron transport chain. In
most aerobic healthy cells, mitochondria are the main source of the reactive
oxygen species (ROS) produced [160-163]. However, due to the high production
of ROS, mitochondria are extremely vulnerable to oxidative damage [164]. Well
aligned with MFRTA is the understanding that one of the primary hallmarks of
aging is mitochondrial dysfunction [161, 165]. The literature suggests that
mitochondrial function is compromised with age in the human brain [158, 159,
166, 167]. In normal aging, mitochondrial respiratory chain activity declines [168],
mitochondrial metabolism-associated enzymatic activity such as aconitase
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decreases [169] and the rate of somatic mitochondrial DNA (mtDNA) mutations
increases [14, 170].
MFRTA was the first theory of its kind to acknowledge a possible link
between mitochondrial oxidative phosphorylation, ROS production, cellular
damage and functional deficits related to aging [171]. In this theory, it is proposed
that mitochondrial produced ROS will diffuse away from the site of production to
damage proteins and mtDNA. This leads to increased damage to proteins within
the ETC, resulting in continually increased ROS production as electron slippage
occurs by the damaged proteins [15, 172]. Therefore, mitochondrial dysfunction
and the production of ROS, combined with lower endogenous antioxidant activity,
may lead to increasing oxidative damage to molecules critically important to
neuronal function. The combination of mitochondrial dysfunction and production
of ROS may be a key contributor to the deleterious effects of aging on the brain
[14, 167, 173-179].

This mitochondrial dysfunction can lead to increased

oxidative stress, changes in protein processing and changes in metabolism.
Although there is evidence arising that contradicts the Dr. Harman’s MFRTA,
there are still many supporters [171], This will be the mechanistic foundation
used in this chapter to explain the deficits seen related to aging and the
therapeutic rational for antioxidants and mitochondrial co-factors to improve
aging and decrease the onset of cognitive disorders.
Age Related Cellular Dysfunction as a causation for Neurodegenerative
Diseases
Many diseased states are thought to be precipitated by increased
oxidative stress within the cell causing damage and consequently dysfunction.
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This is congruent with the MFRTA which was discussed earlier. Further
elaboration on this theory helps to explain the pathology seen in Alzheimer’s
Disease [180] since oxidative damage has specifically been linked to ageassociated neurodegenerative diseases such as Alzheimer’s disease (AD) [181183]. AD is a progressive neurodegenerative disease that causes dementia in
the elderly, affecting an estimated 5.5 million people in the United States [184]. It
is characterized by the accumulation of beta-amyloid (Aβ) in extracellular senile
plaques and intracellular hyperphosphorylated tau protein in neurofibrillary
tangles [185]. Consequently, extensive neuron loss is observed in the AD brain
in the cortex and particularly within the hippocampus, a region of the brain
involved with memory. In an AD affected brain, further increases in oxidative
damage to protein [141, 144, 145, 186-193], lipid [142, 147, 194-197], DNA [198200] and RNA [175, 201, 202] are seen relative to elderly controls. In addition,
endogenous antioxidant activity in the AD brain is reduced relative to agematched controls [141, 146, 203]. Proteins particularly vulnerable to oxidative
damage have been identified by proteomics, with a subset of these proteins
putatively involved directly or indirectly in the production and accumulation of AD
neuropathology [204].
Mitochondrial dysfunction also occurs in AD, with decreased respiratory
chain activity [177, 205, 206] and increased mitochondrial DNA mutations [207]
observed at higher rates when compared to age-matched controls. Further,
decreased cytochrome oxidase activity in the posterior cingulate cortex of AD
patients is correlated with hypometabolism seen by positron emission studies
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[149]. A gene array study in the cingulate cortex shows that energy-metabolism
related genes decrease in AD, with a 65% reduction in expression of
mitochondrial electron transport chain genes [148].
The mitochondrial dysfunction related to AD is further explained in the
literature by a theory called the “Calcium hypothesis of AD”. As mentioned
earlier, mitochondria are bioenergetically active due to the maintenance of a
membrane potential that is primarily generated by the electron transport chain.
As a result of this membrane potential, mitochondria are the cell’s best Calcium
buffering mechanisms. As Calcium enters the cell, mitochondria are able to
quickly uptake the Calcium in an electrogenic fashion. In the Calcium hypothesis
of AD, mitochondria are inherently dysfunctional, therefore hindering their ability
to generate the membrane potential necessary to properly buffer intracellular
calcium. As cytosolic Calcium levels remain high, signaling cascades that affect
synaptic stability and function are initiated, such as the activation of calcineurins
and calpains, leading to detrimental neuronal health [208]. Based on the MFRTA,
the initial mitochondrial dysfunction that inhibits proper Calcium buffering is the
result of mitochondrial oxidative stress within the electron transport chain leading
to diminished membrane potential.

Without the generation of an appropriate

membrane potential, mitochondria are unable to buffer calcium.
Based on these mechanistic theories that eloquently link mitochondrial
function, oxidative stress and metabolism to aging and AD, diet seems to be an
important factor in healthy aging. It is thought that proper dietary supplementation
may hinder the onset of many age-related neurodegenerative diseases such as
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AD. For instance, antioxidants are a critical component of the proper cellular
homeostasis. These compounds are necessary for keeping levels of oxidative
stress low and therefore decreasing damage to lipid, proteins, DNA and RNA
[209]. Based on correlative human neuropathology studies, antioxidants are
predictive of healthy aging, may reduce the risk of developing AD and may
improve cognitive function in AD patients. However, studies in humans have
shown either a positive effect of antioxidant use on cognition and risk reduction
for developing AD [210-212] or no significant effects [213-216]. Few systematic
and controlled clinical trials have evaluated the effects of antioxidants on
cognition in aged individuals or patients with AD.
Dietary Supplementation that target mitochondrial function to improve age
related deficits
As mentioned previously, mitochondria dysfunction, oxidative stress and
changes in metabolism are important factors in natural aging. Based on the
MFRTA, it is thought that appropriate dietary supplementation can help to avoid
many of the age related deficits that arise, such as reduced cognition. Two major
supplementations that have shown some promise are the use of antioxidants as
well as mitochondrial co-factors.
One specific antioxidant which has been well studied in aging and various
age related neurodegenerative states is vitamin E. Vitamin E is an important
lipid-soluble antioxidant that is obtained through the diet [217]. Commonly
referred to as tocopherol, these vitamin E isomers are found in high
concentrations in almonds, roasted sunflower seeds, various plant oils, such as
olive oil, and can also be taken as a supplement. It is thought that proper
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supplementation with Vitamin E can protect cells against deteriorating effects of
oxidative damage and the progression of degenerative diseases and aging
however findings in the literature has shown mixed results [209]. As a compound,
vitamin E is an important antioxidant shown to protect against lipid peroxidation
in cell culture models [218]. However in single-cell organisms, rotifers,
Caenorhabditis elegans, Drosophila melanogaster and rodent models, vitamin E
has shown the full gamut of results, being increased lifespan with
supplementation, no observed changes in lifespan and detrimental effects with
supplementation [219-231]. Similar to these previous finding, human clinical trials
with vitamin E has also produced mixed results. In one study, intake of vitamin E
delayed institutionalization of AD patients [232], suggesting some beneficial
effects. However, vitamin E alone did not improve cognition in patients with mild
cognitive impairment, which is thought to precede AD [233]. Further, in nondemented elderly women, vitamin E treatment was associated with little
improvement in cognition [215].
Vitamin C is another antioxidant that has been studied for years but has
shown mixed results in the treatment of various age related diseases. Since
vitamin C is a water-soluble vitamin, it is not stored in the body and therefore is
needed to be consumed regularly through diet. Not only has it shown to be
important in the maintenance of connective tissues, it can also assist in
the conversion of the amino acid, tryptophan, to the neurotransmitter, serotonin
and is an antioxidant that protects body from free radical damage [234]. Foods
rich in vitamin C are guava, kale and kiwi. To date, research using vitamin C as
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an antioxidant are mixed and seemingly are improved when combined with other
antioxidants such as vitamin E [235]. Research has found that in low
concentrations, it has antioxidant properties, however at high concentrations is a
potent pro-oxidant, with intra- and extracellular mechanisms that generate
hydrogen peroxide [236]. Treatment with aspirin plus ascorbic acid/vitamin C in
aged rats was also shown to enhance cognitive performance and increase the
expressions of several receptors related to learning and memory process [237].
Another recent rodent student also saw that high supplementation of vitamin C
was able to decrease the amyloid plaques found in the cortex and hippocampus
of an AD transgenic mouse model that normally has increased amyloid plaques
in the brain compared to wild-type mice [238]. However, even with the positive
results found in animal testing, the results pertaining to human clinical trials are
not as positive [239]. As study performed in Germany found that vitamin C and βcarotene concentrations were significantly lower in the blood of demented than in
control persons [240].
Coenzyme Q10, which is also known as CoQ10, is another important
naturally occurring compound that has be hypothesized as an integral
component of various neurodegenerative diseases and cognitive disorders
related to age [241]. As an important cofactor needed in the mitochondrial
electron transport chain, CoQ10 is necessary for proper aerobic cellular
respiration and ATP production, both which have been found to decline with age.
It is thought that when CoQ10 is deficient, mitochondrial function decreases,
ROS production increases and inflammation ensues [184, 242].
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Also, in its

reduced form, CoQ10H2 is a fat-soluble antioxidant that is generally found in cell
membranes. This important lipid soluble antioxidant is the only antioxidant that
animal cells synthesize de novo [243]. Although it has an integral role in proper
cellular function related to both metabolism and oxidative stress, its importance in
aging and proper supplementation in many diseased states is highly debated. In
laboratory studies where CoQ10 was supplemented in cell-culture and sliceculture studies, it has been found to be neuroprotective through the reduction of
oxidative stress leading to decreased cell death [244]. Rodent studies have also
shown improvements in cognition with later life supplementation of CoQ10 [245].
Additionally, a study measuring cognition in aged beagles following statin usage
found lower levels of serum CoQ10 in the parietal cortex was correlated with
decreased cognition, suggesting the need for proper CoQ10 level in order to
retain proper cognition [184]. Decreases in plasma CoQ10 levels seen in aged
canines seemingly translate well to humans. A correlative study recently
completed in humans found that plasma levels of CoQ10 are significantly
reduced older patients suggesting decreased antioxidant capacity [246]. Since
both cognition and CoQ10 levels tend to decline with age, it is hypothesized that
decreases in CoQ10 may lead to the mitochondrial dysfunction seen with AD
[247]. However, another interpretation of the data suggests that age related
impaired mitochondrial function which may make aged cells more vulnerable to
naturally occurring decreased levels of CoQ10 [248].
Taken together, studies of dietary or supplemental antioxidant intake in
humans reveal variable results and appear far less robustly associated with
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positive functional outcomes than those reported in the rodent aging literature
[164, 179, 249-256]. Variability in the outcomes of human antioxidant clinical
trials outcomes may reflect inconsistencies in the amount of supplements
provided, their form and source (e.g. lower AD brain neuropathology is
associated with cerebrospinal fluid levels of alpha-tocopherol and not gammatocopherol [257]), their duration and regularity of use and challenges in
determining the exact background of dietary antioxidants [258]. Interestingly,
combinations

of

antioxidants

may

be

superior

to

single

compound

supplementation [259] and dietary intake of antioxidants is superior to
supplements in human studies on cognition and risk of developing AD [260, 261].
Further, supplementation of elderly women with a combination of vitamins E and
C can lead to improved memory [262]. Thus, antioxidants may prove to be more
efficacious if administered in combination with other antioxidants (e.g. vitamin C,
which helps to recycle Vitamin E) and through diet, rather than as a supplement.
In addition to investigating the effects of cellular antioxidants on cognition
and risk of AD, several studies examined the effects of targeted co-factors that
improve mitochondrial function, including acetylcarnitine (ALCAR) and lipoic acid
(LA). ALCAR and LA may improve mitochondrial function and reduce the
production of ROS, thus also reducing oxidative damage to proteins, lipids and
DNA/RNA [263]. In studies where ALCAR was administered to patients with
moderate to severe AD, either improved cognition and/or slower deterioration
was observed [264-267]. In early-onset AD patients (less than 65 years of age),
only small cognitive improvements were noted [268], although younger patients
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with AD (less than 61 years) may also have experienced slowed disease
progression [269, 270]. When the results of all these studies are combined in a
meta-analysis, ALCAR administration in patients with AD was clearly beneficial,
particularly with respect to slowing cognitive decline [271]. Further, combining
ALCAR with acetylcholinesterase therapy in AD may provide additional benefits
[272]. Similar evidence of maintenance of function was observed in an open label
study of 9 patients with AD or related dementias receiving 600 mg/day of LA for
an average of 337 days [273]. In a larger follow up study of 48 patients for a 48
month treatment period, maintenance of function was also observed [274].
A panel of experts for the Duke Evidence-based Practice Center for the
US Department of Health and Human Services recently reviewed the literature
and, not surprisingly, reported no consistent or robust evidence to suggest that
single or dual antioxidant use is protective against AD [275]. In terms of
preventing cognitive decline with aging, vegetable intake was only weakly
associated with decreased risk of developing AD, whereas cognitive training was
strongly associated with decreased risk. Thus, the role of either dietary or
supplemental antioxidants and level of protection against cognitive decline or AD
has yet to be clearly established. Additional reasons for the small or negative
effects of antioxidants on cognition in the elderly and for treatment of AD [249,
276] include the limitations of animal models (primarily rodent) in terms of ability
to predict human response. Therefore, it is useful to consider other animal
models of human aging and AD, and also to test the potential for combinations of
antioxidants/ mitochondrial co-factors to improve cognition and reduce Aβ.
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Specifically, dogs are frequently used to evaluate safety of drugs and in food
metabolism studies given their substantial similarities to humans. Therefore,
preclinical studies of mitochondrial function and interventions should be
completed in an aging canine model of human brain aging and AD to give results
that can better be translated to humans.
Targeting Oxidative Stress in a Canine Model of AD
Dogs may be particularly useful in studying human brain aging because
they naturally develop cognitive decline with age, accumulate oxidative damage
and Aβ protein [277]. In dog brain, oxidative damage to proteins increases with
age [278, 279] and is associated with reduced endogenous antioxidant enzyme
activity or protein levels [278, 280-282]. In several studies, a relation between
age and increased oxidative damage has been inferred by measuring the amount
of end products of lipid peroxidation to predict oxidative damage to lipids. These
end products including 4-hydroxynonenal [282-285] and malondialdehyde [278].
Additionally, we and others have reported evidence of increased oxidative
damage to DNA or RNA (8OHdG) in aged dog brain [277, 285].
Oxidative damage may also be associated with behavioral decline in dogs.
Rofina and collaborators examined oxidative end products (lipofuscin-like
pigment and protein carbonyls) in aged companion dog brain and found a
correlation between increased oxidative end products and severity of behavior
changes due to cognitive dysfunction [279, 284, 285]. Similarly, in work
completed by Opii and Head et. al. aging beagles, higher protein oxidative
damage (3-nitrotyrosine) and lower endogenous antioxidant capacity (superoxide
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dismutase and glutathione-S-transferase) are associated with poorer prefrontaldependent and spatial learning [281]. These correlative studies suggest a link
between cognition and progressive oxidative damage in the dog, suggesting their
utility in testing antioxidant treatment strategies.
To test the hypothesis that reduced oxidative stress leads to cognitive
benefits, longitudinal studies in aged dogs were completed. In this study, a
combination of antioxidants and mitochondrial co-factors was provided in food
[286-290]. 48 aged beagles (between ~8-12 years) were divided into four groups
that were balanced with respect to baseline cognitive ability, sex and age: (1) no
behavioral enrichment/control diet group; (2) behavioral enrichment/control diet;
(3) no behavioral enrichment/antioxidant diet; and (4) combined behavioral
enrichment and antioxidant diet. In a subset of experiments, an additional 17
young beagles (<5 years of age) were included for comparison to aged dogs.
Young dogs were all placed in the behavioral enrichment condition, with half
provided with the antioxidant diet (i.e. similar to groups 2 and 4).
Three unique features of the experiment included: 1) a combination of
antioxidants and mitochondrial co-factors; 2) incorporation of all antioxidants and
mitochondrial co-factors into food and; 3) evaluation of dietary treatments in
combination with behavioral enrichment. An antioxidant-enriched dog diet was
formulated to include a broad spectrum of antioxidants and two mitochondrial cofactors [289]. Based on an average weight of 10 kg per animal, the daily doses
for each compound were 800 IU or 210 mg/day (21 mg/kg/day) of vitamin E, 16
mg/day (1.6 mg/kg/day) of vitamin C, 52 mg/day (5.2 mg/kg/day) of carnitine and
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26 mg/day (2.6 mg/kg/day) of lipoic acid. Fruits and vegetables were also
incorporated at a 1 to 1 exchange ratio for corn, resulting in 1% inclusions
(dehydrated) of each of the following: spinach flakes, tomato pomace, grape
pomace, carrot granules and citrus pulp. This was equivalent to raising fruits and
vegetable intake from 3 servings per day to 5-6 servings per day based upon
ORAC values [291]. Additionally, vitamin E was increased by ~75% in dogs
treated with the antioxidant diet [292]. The behavioral enrichment condition
consisted of additional cognitive experience (20-30 min/day, 5 days/week), an
enriched sensory environment (housing with a kennel-mate, weekly rotation of
play toys in kennel) and physical exercise (two 20 min outdoor walks/week)
[289].
Dogs were evaluated over a 2.8 year period to evaluate short term and
chronic treatment effects. Treatment with the antioxidant diet lead to cognitive
improvements in learning within two weeks, with aged animals showing
significant improvements in spatial attention (landmark task) [292]. Subsequent
testing of animals with a more difficult complex learning task (oddity
discrimination) also revealed benefits of the diet [286]. With antioxidant
treatment, visual discrimination improved and reversal (frontal function) learning
ability was maintained over time while untreated animals showed a progressive
decline [289]. This was despite the fact that for each time point where
discrimination learning was re-administered, the task was made more difficult
(harder to distinguish objects) to prevent a practice effect. Thus the progressive
increase in error scores over time in untreated dogs reflects both increased task
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difficulty and possibly, longitudinal aging effects. Interestingly, the dogs fed an
antioxidant diet benefited from behavioral enrichment, in that cognitive scores of
aged dogs receiving both treatments were superior to either treatment alone
[288, 289]. For example, in singly treated animals spatial memory showed a
trend toward improvement, reaching statistical significance only after long-term
treatment (>2 years) with a combination of both the antioxidant diet and
behavioral enrichment [290]. The antioxidant diet selectively repaired an aging
deficit, in that cognitive scores from young dogs treated with the antioxidant diet
did not differ from those of young dogs fed control diet [293].
Neurobiological studies showed reduced oxidative damage and increased
endogenous antioxidant activity in antioxidant-fed dogs, particularly among
animals receiving the combination of antioxidants and behavioral enrichment
[281]. Interestingly, the antioxidant diet increased the levels of glutathione
suggesting a possible involvement of a possible vitagene network that might
account for the increased expression of antioxidant molecules and growth
proteins [294, 295]. Given that the diet provided to the dogs also included
acetylcarnitine, resulting in increased levels of heme oxygenase (HO-1) also
support the possibility that vitagene networks are engaged [294].
Mitochondrial function was significantly improved in the antioxidant fed
dogs and not in behaviorally enriched dogs [248]. Interestingly, behavioral
enrichment but not the antioxidant diet protected against neuron loss in the hilus
of the dog hippocampus [296]. Further, brain derived neurotrophic factor mRNA
increased in aged dogs provided with the combination treatment [297]. These
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results suggest that cognitive benefits of antioxidants can be further enhanced
with the addition of behavioral enrichment, perhaps due to different yet
synergistic mechanisms of action in the brain, including reduced oxidative
damage and maintenance of neuron health.

In addition to brain, however,

peripheral benefits were also seen, including less cellular degeneration in the
inner ear [298].
Interestingly, in a recent study of aged dogs, the formulation of the diet
was modified to compare only the mitochondrial co-factors used in this previous
study and effects on cognition [299]. Aged dogs were treated with lipoic acid,
ALCAR

or

the

combination

and

tested

with

spatial

learning

and

discrimination/reversal tasks. When these compounds were included with a
broader spectrum of antioxidants described above, no cognitive benefits were
observed when evaluated singly or in combination. Additionally, protein carbonyl
accumulation in the plasma of treated dogs was increased. Increased oxidative
damage may reflect either higher doses of the mitochondrial co-factors used in
this study or increased oxidative stress resulting from not counterbalancing
mitochondrial cofactors with cellular antioxidants.
Changes in mitochondrial bioenergetics that occur with age
Through this Calcium mediated mitochondrial cell death mechanism and
others,

mitochondria

have

been

implicated

in

various

age

related

neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, ALS [300].
Therefore, scientists have turned their interests to finding novel therapeutic
approaches in order to target mitochondrial function with the hopes of avoiding

72

the onset and/or progression of diseases where mitochondrial dysfunction is
present and amendable. However, as scientists discovered approaches that
were able to target mitochondrial function, a debate ensued as to whether
mitochondria are a homogenous population across various tissue types.
With the investigation of mitochondrial targeting therapeutic approaches
for various disease states, unexpected insights into the nature of mitochondria
have surfaced. Mitochondrial function does not seem to be consistent across all
tissue types or even within different regions of a specific cell type, specifically
synaptic versus non-synaptic mitochondria [301]. Additionally, it is also thought
that aging further increases these differences [300]. Therefore, to date, the field
is beginning to probe the idea that mitochondria may not all be alike and may
react to insults, such as aging or toxins, differentially. Within this article, we will
review these differences and highlight new data supporting this hypothesis from
our laboratory.
Based on the information provided previously, mitochondrial bioenergetics
and age related changes to these bioenergetics is an important area of research.
Denham Harman’s work on the Mitochondrial Free Radical Theory of Aging
(MFRTA) [139, 150, 158-160, 302] is heavily debated, however there are
specifics that have yet to be disproven. Within MFRTA, Harman acknowledged
that through the normal function of the electron transport chain, reactive
electrons are released. These electrons are then able to react with free oxygen,
generating reactive oxygen species, which can thereby react with nearby
proteins, nucleic acids, etc. leadings to metabolic mediated oxidative stress. Over
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time, the oxidative insult perpetuates and mitochondrial and cellular damage can
occur. After many years, this damage begins to accumulate leading to decreased
bioenergetics efficiency, increased electron slippage/release and decreased ATP
production. In cell types with low bioenergetics profiles, this change in
bioenergetics is not a large concern. However, in cells that have a high energy
demand such as neurons, decreased ATP production can lead to serious
detrimental effects which can result in severe functional changes due to
disruption of cellular homeostasis.
Age-associated impairments in mitochondrial oxidative phosphorylation
(OXPHOS) due to oxidative damage has been shown in multiple tissues
including the brain, muscle, liver and heart [205, 303-306].

However, the

proteins damaged seem to be very specific and not necessarily the result of a
complete destruction to all mitochondrial structures. Therefore, specific
mitochondrial proteins seem to be more vulnerable to age-related metabolic
mediated oxidative stress. For instance, mitochondria isolated from various
rodent tissues have shown decreased mitochondrial electron transport chain
enzymatic activity with age, specifically within complexes I and IV, however
complexes II and III seemingly remain unaffected [307, 308]. Based on data
obtained from our laboratory, it has also become apparent that age related
mitochondrial dysfunction may be the result of a regional specific dysregulation in
Calcium buffering by the mitochondria [300]. In this specific study, mitochondria
isolated from aged rat cortex and hippocampus showed increased ROS
production and decreased Calcium buffering capacity compared to young rats
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however this was not observed in mitochondria isolated from the cerebellum of
these animals. This study also found that aged brain mitochondria were able to
undergo mitochondrial permeability at a lower Calcium threshold than young
animals with the exception of cerebellar mitochondria where no difference was
measured.
It is thought that as oxidative damage and the resulting mitochondrial
dysfunction increases with age, mitochondria will become more vulnerable to
insults by environmental toxins, etc. leading to an increase in mitochondrial
mediated cell death. This rational is supported by the increased prevalence of
neurodegenerative diseases in the aged population [102]. Additionally, these
age-related changes in mitochondrial bioenergetics do not seem to occur equally
in all regions of the central nervous system. Certain regions within the central
nervous system experience increased mitochondrial dysfunction, increased ROS
concentrations and decreased Calcium buffering capacity making these tissue
types more vulnerable to the initiation of mitochondrial mediated cell death
pathways.
Mitochondrial differences in the brain versus spinal cord
Back in the early 2000s, our laboratory and others were investigating
Cyclosporin A for the treatment of injuries to the central nervous system, CNS. At
the time, Cyclosporin A was a known immunosuppressant however it also had a
secondary target within the mitochondria. Specifically, it was found to bind a
protein within the mitochondria called Cyclophilin D, thereby inhibiting the
mitochondrial permeability transition. In the model of brain injury, this drug
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provided a means of limiting part of the excitotoxic cell death cascade that occurs
following injury. However, within these studies it was noticed that the therapeutic
effect of Cyclosporin A was lost when it was moved from brain injury to a model
of spinal cord injury. This work provided evidence that mitochondria in one tissue
type differs from mitochondria within another tissue [300]. Upon further research,
it became apparent that these differences could also occur in tissues that were
histologically similar. For instance, the brain and the spinal cord are one
continuous structure, thereby sharing similar cell types. However, it has been
shown that mitochondrial from the brain have different bioenergetics than those
in the spinal cord. Later it became apparent that even mitochondria within one
area of a cell can have a different energetic profiles compared to mitochondria
within another area of cell. Specifically, our work has shown that neuronal
mitochondria located in the synapse of neurons have different bioenergetics,
calcium buffering capacities and respond differently to mitochondrial targeting
drugs compared to mitochondria found within non-synaptic pools [39, 301, 309314]. This data further supports the theory that mitochondrial bioenergetics may
be location specific.
From our current understanding, it seems as if there is convincing
evidence supporting the theory that mitochondria within the spinal cord may have
significant differences in metabolic profiles than mitochondria within the brain.
Work from our laboratory and others have found that mitochondria within the
spinal cord produce more reactive oxygen species and have increased oxidative
damage compared to age-matched brain mitochondria. Additionally, in normal,
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non-aged mitochondria obtained from 3 month old rats, spinal cord mitochondria
have decreased maximum NADH linked mitochondrial respiration. However, in
this study no difference in FADH2/succinate mediated respiration was
demonstrated [313]. Additionally, spinal cord mitochondria have a lower calcium
mediated threshold for the formation of the mitochondrial permeability transition
pore, which is likely related to increased expression of cyclophilin D compared to
brain mitochondria. Because of these differences, drugs that inhibit the formation
of the mitochondrial permeability transition pore such as Cyclosporin A require
significantly higher concentrations in order to provide the same degree of
neuroprotection in the spinal cord that is seen in the brain. Although these
findings were interesting, they lead to more questions. Specifically, does age
influence the differences seen between mitochondria from the brain versus the
spinal cord?
Age related differences between brain and spinal cord mitochondria
We hypothesized that since age and location of mitochondria both have
individual effects on mitochondrial bioenergetics, then when combined together
an even further deviation in mitochondrial function will occur. To test this
hypothesis we compared mitochondrial bioenergetics within the brain to those
within the spinal cord in rats at different ages, specifically 3 month compared to
12-15 month old male Sprague-Dawley rats (9 per age group, tissue from 3
animals pooled for mitochondrial assessments). Within this study we looked at
differences in the total mitochondrial population within the cortex of the brain and
cervical, thoracic and lumbar regions of the spinal cord using techniques as
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described in [39, 300, 301, 313]. Analysis of the NADH-linked maximum
respiration data using a 2way ANOVA demonstrated a significant age X region
interaction (F=4.955, p = 0.012) as well as significant effects of age (F=72.69, p <
0.0001) and region (F=39.46, p < 0.0001). FADH2-linked maximum respiration
demonstrated significant effects of age (F=31.30, p < 0.0001) and region
(F=29.68, p < 0.0001) with no significant age X region interaction (F=3.238, p =
0.050). To further establish age dependent differences, unpaired t-tests were
performed for each region in young vs aged animals. We determined aged rats
had a 20 to 50% decrease in NADH mediated respiration within all regions of the
spinal cord compared to the young cohort (p < 0.05). Aged animals also showed
a significant decrease in succinate/FADH2 mediated respiration within the
various regions of the spinal cord (p < 0.05), which was not demonstrated in the
brain for either NADH or FADH2 mediated respiration (FIGURE 2-1A and 2-1B
and TABLE 2-1). These findings are very interesting because significant NADH
mediated inhibition of cortical mitochondria has been documented with age in the
past however this study did not find the same conclusions [300]. The differences
observed however may be due to inherent strain differences and/or the ages of
animals examined in these two studies. We did, however, find a significant
decrease in both NADH and FADH2 mediated respiration in all the tested areas
of the spinal cord in the aged animals compared to young. With the results found
in young animals, mitochondria within the spinal cord seem to have decreased
bioenergetics, compared to brain mitochondria, which continues to decrease with
age. This decrease in bioenergetics has the potential of making these areas
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more vulnerable to insults due to decreased energetic reserves, deceased ATP
production and decreased capacity for ROS, which would increase the probability
of a transition to cell death and therefore, increase the possibility of
neurodegeneration.
Mitochondrial mediated oxidative stress and mitochondrial dysfunction
generally occur together however the causation between the two is debated,
however MFRTA supports the theory that oxidative stress causes mitochondrial
dysfunction. To further support this hypothesis that the deviations in
mitochondrial respiration are the result of oxidative stress, we assessed
mitochondrial ROS production as a function of age across CNS regions using
methods previously described in [39, 301]. A 2way ANOVA of basal
mitochondrial ROS production demonstrated a significant age X region
interaction (F=12.81, p = 0.0002) as well as significant effects of age (F=183.6, p
< 0.0001) and region (F=16.10, p < 0.0001). Unpaired t-tests revealed that
mitochondria isolated from aged rats compared to young rats (12 months
compared to 3 month old Sprague-Dawley rats) had a significant (p < 0.01)
increase in reactive oxygen species (ROS) production within all regions of the
CNS, specifically the cortex and the cervical, thoracic and lumbar regions of the
spinal cord (FIGURE 2-2 and TABLE 2-2). One factor that is ambiguous within
this study is whether the high ROS production leads to decreased mitochondrial
bioenergetics or the decreased bioenergetics leads to increased ROS
production. However, what is known is that this age related increase in ROS can
eventually lead to cellular dysfunction making aged animals more vulnerable to
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cellular insults. This increased vulnerability makes the animal more likely to
experience cellular dysfunction and possibly cellular death within this region.
With increased production of ROS and decreased mitochondrial
respiration, mitochondrial and cellular structures become more vulnerable to
oxidative damage. As previously reported by our group, mitochondrial DNA,
mtDNA, damage is significantly higher within the spinal cords compared to the
brain [313]. This increased damage to mtDNA can further perpetuate the
mitochondrial dysfunction observed since protein structures made within the
mitochondria have an increased chance of being mutated which can render
mitochondrial proteins encoded by the mtDNA dysfunctional.
Summary
Well supported by the literature and the studies conducted in our lab,
NADH and FADH2 mediated mitochondrial respiration decreases in the cortex
and within the cervical, thoracic and lumbar regions of the spinal cord as age
increases. In addition to changes in respiration, we have also observed
increased mitochondrial ROS production with age in these same regions. Lastly,
within the spinal cord of aged animals, it seems as in mtDNA damage is
increased which could be a direct result of the increased mitochondrial ROS
production. Although more studies may be needed to determine the exact age
when the mitochondria become less bioenergetically efficient and to determine
whether ROS or mitochondrial bioenergetics increase first with age leading to the
other, MFRTA and the previously mentioned studies do give great insight into a
potential therapeutic target that scientists could exploit in order to improve age
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related functional decline and thereby improving the quality of life for the older
population.
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Young Cortex
Young Cervical
Young
Thoracic
Young Lumbar
Aged Cortex
Aged Cervical
Aged Thoracic
Aged Lumbar

TABLE 2-1: Mitochondrial Mediated Respiration
Mean (nmol oxygen/min/mg) + SD
State III
State IV
State V
94.64 + 4.61
16.09 + 1.42
114.09 + 5.50
70.67 + 7.72
10.73 + 1.88
94.44 + 13.19
42.32 + 3.99
7.75 + 1.06
81.97 + 2.80

State Vsuc
125.46 + 1.77
100.16 + 14.02
85.60 + 4.36

48.52 + 11.80
85.29 + 14.47
38.06 + 8.52
26.38 + 8.57
31.31 + 4.32

77.79 + 5.74
118.01 + 11.43
52.44 + 19.15
58.70 + 13.67
56.10 + 9.79

7.96 + 0.70
17.87 + 5.67
9.34 + 2.49
5.58 + 1.82
5.44 + 1.34

72.24 + 11.29
102.98 + 4.72
45.73 + 9.69
45.40 + 10.51
46.29 + 7.20

TABLE 2-2: Tissue Specific ROS Production
Mean (DCF Flourescence AU/µg) + SD
Young Cortex
95.88 + 9.24
Young Cervical
121.95 + 32.61
Young Thoracic
145.28 + 39.95
Young Lumbar
144.95 + 61.75
Aged Cortex
235.30 + 45.52
Aged Cervical
625.79 + 63.73
Aged Thoracic
293.04 + 78.52
Aged Lumbar
485.65 + 52.79

83

FIGURE 2-1
A

M a x N A D H - lin k e d R e s p ir a t io n
1 2 - 1 5 M o n t h O ld N a i v e R a t s
n m o l/m in /m g

% o f Y o u n g R a ts

100
80

*

*

60

*

40
20
0
C o rte x

C e r v ic a l

B r a in

B

T h o r a c ic

Lumbar

S p in a l C o r d

M a x F A D H 2 - l in k e d R e s p ir a t io n
1 2 - 1 5 M o n t h O ld N a i v e R a t s
n m o l/m in /m g

% o f Y o u n g R a ts

100
80

*

*

T h o r a c ic

Lumbar

*

60
40
20
0
C o rte x

B r a in

C e r v ic a l

S p in a l C o r d

84

FIGURE 2-1 Increased age in rats lead to decreases in (a) NADH and (b)
FADH2 mediated respiration.
Total mitochondria were isolated from young (3 month) and aged (12-15 months)
male Sprague-Dawley rats (9 per age group, tissue from 3 animals pooled for
final n=3 per group) and oxygen consumption assessed in a sealed, stirred,
thermostated chamber equipped with a Clark-type electrode and expressed as
nmol of oxygen consumed per min per mg of mitochondrial protein. Maximum
NADH-linked (A) and FADH2-linked (B) respiration data were then analyzed
using 2-way ANOVAs following by unpaired t-tests when warranted to assess
age effects on mitochondrial bioenergetics. Data are expressed as % of
respiration measured in young animals, *p < 0.05.
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FIGURE 2-2
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FIGURE 2-2: Mitochondrial ROS production increases with age.
Aged rats had a 200% to 600% increase in ROS production mitochondria
isolated from the cortex and spinal cord compared to young rats. Total
mitochondria were isolated from young (3 month) and aged (12-15 months) male
Sprague-Dawley rats (9 per age group, tissue from 3 animals pooled for final n=3
per group) and ROS production assessed using the indicator DCF in the
presence of respiratory substrates. Control wells included FCCP to induce
minimum ROS production and oligomycin to induce maximum ROS production.
Wells in which mitochondria were omitted were used for background subtraction.
Raw data (DCF fluorescence AU/ug) were then analyzed using a 2way ANOVA
following by unpaired t-tests when warranted to assess age effects on
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mitochondrial basal ROS production. Data are expressed as % of respiration
demonstrated in young animals, *p < 0.05.
Portions of this chapter have been previously published in:
Yonutas HM, Pandya JD, Sullivan PG; Changes in mitochondrial bioenergetics
in the brain versus spinal cord become more apparent with age. J Bioenerg
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PMID: 25472025; PubMed Central PMCID: PMC4323922
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CHAPTER 3: TRAUMATIC BRAIN INJURY
In the United States, the CDC estimates that approximately 1.7 million
Americans experience a traumatic brain injury (TBI) every year [315]. Expanding
this scope, it has been further estimated that 57 million people have experienced
a brain injury worldwide [315, 316]. Even more astounding is that these numbers
do not account for the population who sustain a TBI, likely more mild in nature,
and do not seek medical care. With such a large affected population, it is
estimated that approximately 77 billion dollars are spent annually on direct and
indirect health related costs in the US alone [316]. Therefore, it becomes obvious
that there is a great need for pro-regenerative and/or neuroprotective therapeutic
agents for the treatment of this disease however to date there is still no FDA
approved drug for its treatment. Although ample manpower has gone into the
discovery of drugs to treat TBI, many tribulations have been encountered along
the way due to the multifaceted complicated set of pathways that are initiated
following the primary the injury.
The pathophysiology of TBI
The pathophysiological nature of TBI is complicated and is thought to
occur in a biphasic manner. The first phase is termed the primary injury and the
second phase is termed the secondary injury.
Primary Injury
initial impact is where kinetic energy is transferred into a mechanical
disruption within the brain causing immediate tissue damage. The extent of
damage, and therefore the severity of the injury, depends on the nature of the
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injury as well as the degree of mechanical force transferred to the brain tissue
when the injury ensues. One complication that physician and researchers
encounter when attempting to treat this disease is that injuries are generally
heterogeneous in nature, providing a “significant barrier” for therapeutic
interventions [317]. According the the Mayo Clinic, injuries may include one or
more of the following factors:
1) Tissue damage limited to an acute area directly below the
point of impact on the skull. This type of injury is often referred to as a
contusion injury.
2) Tissue damage at multiple points in the brain due to
movement of the cerebrum, brain stem, and cerebellum within the
cranial vault, which is defined as a coup contrecoup injury.
3) Tearing of cellular structures due to severe rotational
movement or spinning motion. This type of injury can often include a
coup contra-coup injury as well as damage to deeper cerebral
structures. This is often called a rotational injury.
4) Widespread tissue damage due to a blast from an explosive
device. This is defined as a blast injury.
5) Tissue damage can occur as the result of an object
penetrating the skull such as a bullet or some other rigid structure with
enough kinetic energy to break the skull. This type of injury can often
be referred to as a ballistic injury, when referring to a bullet, or produce
a contusion type of injury as well.
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6) Changes in vasculature such as bleeding in and/or around
the brain, swelling of the brain and blood clots which disrupt the
oxygen supply also causing tissue damage.
7) Lastly, which was not noted by the Mayo Clinic, brain
damage can occur as the result of drowning or any other environment
where oxygen supply to the brain is diminished. This is defined as an
anoxic or hypoxic type of TBI.
These types of primary injuries are most commonly produced by either
falls, vehicle related-collisions, assault, sports injuries or explosive blast or other
combat related injuries.
To date, there are a few known risk factors that increase a person’s
chances of sustaining a TBI. One of the first risk factors is age including children
from newborn to 4 years old, young male adults between the ages of 15 to 24,
and adults ages 75 and older [318]. The rate of TBIs per 100,000 in the US
population is also greater in males, between 25 to 28 over the past decade
compared to females which ranges more between 9 and 10.
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Figure 3.1 Gender is a risk factor for TBI: Based on CDC reports, males have
double the risk of sustaining a TBI compared to females. [319]

91

Drug usage, nutrition and psychosocial status also are included as risk
factors for TBI [320]. Additionally, athletes involved in high impact sports, such as
boxing, football or soccer, and solders involved in military combat have also been
defined as two groups who are more susceptible to sustaining a TBI. Since this
phase of the injury is cannot be therapeutically influenced, the best practice to
avoid the primary injury is through prevention techniques [321]. The CDC
proposed prevention techniques including:
1) Using proper restraints for you and your children while
operating or riding in a motor motor vehicle.
2) Never driving while under the influence of alcohol or drugs.
3) Wear a helmet, or have your children wear helmets, while
a. Riding a bike, motorcycle, snowmobile, scooter, or allterrain vehicle;
b. Playing a contact sport such as football, ice hockey or
boxing;
c. Using in-line skates or riding a skateboard;
d. Riding a horse; or
e. Sking or snowboarding
4) Making living areas safer for seniors by:
a. Removing tripping hazards;
b. Using nonslip mats on surfaces that become slippery
when wet such as bathroom floors, bathtubs, showers, etc.;
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c. Installing handrails in stairways;
d. Proper lighting within the hom
e. Maintaining a physical activity regiment to provide
increased body strength and balance.
5) Making living areas safer for children by:
a. Using window guards on open windows to avoid them
falling out of one
b. Using safety gates at the top and bottom of stairwells.
6) Having safe shock-absorbent floor surfaces around play
areas [321].
In addition to using proper precautions to help avoid the occurrence of a
TBI, researchers have also continued to improve upon current helmet designs.
Researchers have found that a hard shell design alone for helmets will not help
protect the brain from injury. Not surprisingly, the cushion (foam) within the
helmet seems to be of the upmost importance in order to decrease the head
impact acceleration and therefore the mechanical force that the brain encounters
[322]. However, as researchers at the Lawrence Livermore National Laboratory
discovered, there does not seem to be one type of foam that protects against all
injuries. For instance, dense foams within the helmet seem to protect the brain in
to a greater extent when high-speed interactions are observed. On the contrary,
when low speed interactions are encountered, less dense foam seems to
outperform the higher density foam. Additionally, the thickness of the foam within
the helmet is also an important factor in that the thicker the foam, the less force
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the brain will experience during any impact [323]. However, these researchers
also determined that at high enough speeds, the kinetic energy is too high and
no thickness or density of the foam could protect against damage to the brain
[324]. Therefore, although prevention techniques are currently being improved
upon, mechanical insults to the brain tissue are still able to occur leading to
necessary progress being made once the injury occurs.
Even with proper prevention techniques in place, traumatic brain injuries
are still occurring within the US as an alarming rate. When this injury occurs, as
mentioned previously, it starts the injury cascade. This cascade is initiated by the
primary injury leading to tearing of blood vessels, sheering of axons and
immediate cell death which have all been documented and are dependent on the
severity of the impact [325]. The initial insult causes cellular membranes around
the injury to become permeable to various proteins, ions and other molecules
which is thought to be one factor leading to the initiation the secondary phase of
the injury [326].
Following the primary injury, within the first seconds, to minutes, to days
and now seemingly expanding to months and possibly years later is the second
phase of this bi-phasic injury cascade. This phase is often called the secondary
injury cascade and causes delayed non-mechanical tissue damage [327]. This
tissue occurs due to a complex set of events including alterations of endogenous
neurochemical mechanisms, ischemic insult, massive edema, increases in
oxidative stress and mitochondrial dysfunction which all lead to progressive
damage around the site of the primary injury [109]. It is the tissue that is
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undergoing this progressive damage that researcher and physicians have the
greatest interest in when investigating therapeutic interventions following injury. It
is thought that with proper intervention, improved functional outcomes can be
obtained due to decreased tissue dysfunction and neurodegeneration. This
secondary injury cascade will be discussed in more detail later in this chapter.
Experimental Models of TBI
The heterogeneous nature of clinical TBIs has sparked the invention of
many experimental injury models [317].

Contusion injury, coup contra-coup,

rotational injuries, blast injuries, penetrating injuries, anoxic or hypoxic injury,
plus others, as well as combination injuries, have all been documented in clinical
setting. When experimentally investigating these injuries, a single model has not
been shown to be superior so a few of the more commonly used models will be
discussed. However, a concentration will be placed on the contusion injury
modeled by the controlled cortical impact since this was the model used for the
studies in this thesis.
The experimental injury models can be either static or dynamic. A static
injury model in one which produces a compression injury and the force applied is
never removed. Dynamic injury models are the most commonly studied forms of
injury [328, 329]. These injuries can be the result of an indirect force being
applied to the brain, an example of this would be an explosion which is modeled
by the blast wave injury model, or the direct injury model, where there is an
object which interacts with the head to produce the injury. From here, direct injury
models can be further classified as penetrating or non-penetrating models of
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injury. Two well-studied models of dynamic, direct, penetrating injuries are the
fluid percussion model and the controlled cortical impact model [328].
Blast Traumatic Brain Injury, mTBI
The first model discussed will be the blast wave injury model which would
be considered a dynamic non-penetrating injury. This model has gained more
interest due to the marked functional changes observed by the men and women
returning home from the war after encountering a blast or explosion. In this
experimental design, a stabilized animal is attached to the end of cylindrical
metal tube that has a closed on the other side. This close end is where a plastic
explosive or compressed air device is located which can be detonated to produce
the blast wave. The pathology of this form of injury is still highly debated and
therefore is being continually investigated. Following the primary insult, shock
waves from the explosion can pass through the brain tissue leading to minute
neuroanatomical changes [328]. This blast overpressure causes the transfer of
kinetic energy into a force on the brain which is thought to induce afferent
hyperexcitability leading to increase synthesis and release of various
neurotransmitters [330-332]. Although no apparent mitochondrial dysfunction has
been documented in this model, neuron swelling, astroglial response and myelin
debris in the hippocampus have all been observed. Damage to neuronal
cytoskeletal structures in layers II-IV of the temporal cortex, the cingulate gyrus,
the piriform cortex, the dentate gryus and CA1 regions of the hippocampus has
also been seen over 7 days following injury [333]. Increases in oxidative stress,
alterations of antioxidant defense systems, increased nitric oxide metabolism and
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cognitive deficits have also been documented in patients who have sustained a
blast TBI, bTBI. Additionally, compression of blood vessels can also occur
leading to changes in blood flow to the brain, possibly inducing a hypoxic state.
As the blast wave encounters the brain tissue, a coup-contracoup injury
can also occur in which the brain is pushed in the direction of the shock wave
compressing itself along the backside of the cranial cavity. Based on the law of
conservation of energy, once the brain impacts the cranial cavity at the site
opposite to the point of impact, the brain will then move back towards the site of
injury within the cranial cavity. Therefore, this injury causes a coup and
contracoup injury which are 180o from one another.
Fluid Percussion Injury, FPI
The next model of brain injury discussed will be the fluid percussion injury
model, FPI, which is a direct penetrating injury model. In this model, water
confined in a tube is impinged by a weight with a specific kinetic energy. This
generates a pressure pulse in the water. The water is then rapidly injected into
the cranial cavity, through the Luer cap placed in the skull, providing a
mechanical force to the brain that is diffuse in nature [334]. Following injury,
animals experience apnea and the severity of the injury is measured by the
animals “righting time”. Depending on the location of this injury, either midline or
lateral, and the severity, this injury does not produce any overt histopathology or
contusion at the site of injury, however with the lateral fluid percussion, apparent
cavitation and cell death is markedly observed within the ventricular region out to
one year post-injury. As a model, FPI produces an injury that is thought to mimic
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a rotational injury on the brain which can be the result of a clinically traumatic
event such as a car accident or sports related injury.
Controlled Cortical Impact, CCI
The last model discussed, and the most important model related to this
thesis project, produces a much more focal contusion injury compared to the
diffuse injury seen with FPI. This is the controlled cortical impact, CCI, which
uses a rigid impactor which impinges exposed, intact dura producing cortical
tissue loss, acute subdural hematoma, axonal injury, concussion, a breakdown
the of blood brain barrier and coma [329, 335-340]. This experimental models
dates back to the late 1980s where Dr. James Lighthall produced a novel
contusion injury model in ferrets. This open-skull midline injury was generated by
a pneumatic impact device that was attached to a cylinder shaft. The cylinder
shaft had a 1.25cm diameter aluminum rod at the end, which was the tip that
interacted with the brain. Dr. Lighthall then drilled a 1.5cm craniotomy in on the
midline of the skull, between bregma and lambda, to expose the brain tissue.
Great care was taken to remove the drilled bone flap in order to not damage the
dura mater. The brain was then impacted at various velocities producing a
graded injury which became lethal at higher velocities [340].
Then, in 1991, Dr. Edward Dixon, under the advisement of Dr. Ronald
Hayes, expanded upon the work from Dr. Lighthall, generating an experimental
CCI injury model which is most commonly used to study contusion brain injuries
today. This work from Dr. Dixon was completed in rats and provided a very
thorough investigation into the neurological, cardiovascular and histopathological
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changes that occur following a midline contusion injury. The neurological deficits
seen were consistent with changes to somatomotor system, showing decreased
beam balance latencies and increase beam walking latencies which was
dependent on the depth of the impact. These changes in motor function were
also further supported with observations of axonal injury in the cerebellar
peduncles and pontomedullary junction. Changes in mean arterial blood pressure
were also observed leading to hypotension following a moderate injury (2mm
cortical deformation) where a severe injury (3mm cortical deformation) produced
immediate hypertension followed by hypotension. Most importantly noted
however is that this type of injury paradigm could be graded, which was
dependent on the extent of cortical deformation during the impact, leading to
either no overt macroscopic or microscopic changes to the brain when the brain
was only impacted at a depth of 1mm compared to a brain that received a large
cortical contusion and intraparenchymal hemorrhage with a 3mm cortical
defomation [336].
The work from Dr. Lighthall and Dr. Dixon was further expanded upon
when Dr. Douglas Smith, in 1995, used this model to injure the left
parietotemporal cortex in mice. In this study, a 3mm beveled flat-tip metal
impactor tip was used to impinge the brain at a velocity of 5.7-6m/s. With this
injury paradigm, decreased cognition was measured at 2 days post-injury with
the use of the Morris Water Maze. With this cognitive tests, animals are placed in
a tub of water and tasked to remember visual cues around the room to find a
platform hidden under the surface of the water. In support of the changes in
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memory/cognition that was observed, postmortem histological studies from
48hour post-injured mice revealed substantial cortical loss at the site of the
impact and cell loss in the CA2, CA3 and CA3a regions of the hippocampus.
Bilateral degeneration in the gray matter-white matter interface of the corpus
callosum and reactive gliosis was observed bilaterally in the cortex, hippocampus
and thalami at 48 hours post-injury. Additionally, a breakdown of the blood brain
barrier was also documented in the cortex, hippocampus and thalamus [339].
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Figure 3.2 Injury diagram for the CCI model: The controlled cortical
impact model of TBI produces a contusion injury that leads to cell death and
dysfunction acute to the injury. This injured tissue can be found in the cortex,
hippocampus and corpus callosum on the ipsilateral injured hemisphere as well
as the corpus callosum on the contralateral hemisphere [339].
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The controlled cortical impact uses a pneumatic piston with a specific
velocity, depth and dwell time to induce an injury. The severity of the injury can
be adjusted based on these parameters. This injury provides a non-penetrating
deformation to the cortex leading to a hematoma that has a similar
histopathology to a clinical contusion injury, analogous to a lesion due a fall or a
sports related injury. Immediately following the injury, a bruise occurs which
begins to undergo progressive neurodegeneration that can continue to extend
based on the secondary injury cascades for up to years [341]. At this time,
differences in damage to the blood brain barrier, BBB, and cytoskeletal in the
cortex and hippocampal formation have all been seen and well documented
within the secondary injury cascade [342]. Glutamate excitotoxicity, changes in
calcium homeostasis, increased free radical production and lipid peroxidation,
mitochondrial dysfunction, inflammation and apoptosis are all hallmarks of this
injury paradigm and used a potential therapeutic targets following injury [110,
311, 312, 343-354]. .
Secondary Injury Cascade
Following the primary injury is a vast and encompassing secondary injury
cascade that is initiated at various time point post-injury. This secondary injury
cascade arises due to alterations in excitatory amino acids (EAA) such as
glutamate [309, 355], increases in oxidative stress (ROS) [356-358], the
disruption of Calcium homeostasis [359, 360], and mitochondrial dysfunction
[108, 311, 312, 343, 346, 347, 350, 353, 354, 361-364], which can all contribute
to increased tissue damage at the site of the injury. Scientists believe that by
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targeting these secondary injury cascades, improved histological and function
outcomes will follow.
Although a complete understanding of the secondary injury cascade injury
is still uncertain, the implications of abnormally high excitatory amino acids, EAA,
levels around the site of the injury are generally accepted. The most common of
these EAAs is glutamate. High glutamate levels are thought to be a result of the
breakdown of the blood-brain barrier, BBB, excessive synaptic release from
neurons, nearby hyperexcited astrocytes and excitatory amino acids forming
micropores within the cell membrane [365]. Once in the synaptic cleft, these
EAAs are able to activate multiple receptors and channels including, AMPA and
NMDA. Activation of these receptors leads to Calcium influx into the cell. As
mentioned previously, at low to moderate levels, this intracellular Calcium,
[Ca2+]i, is used as a potent signaling molecule; important in many pathways such
as

increased

metabolism,

neurotransmitter

release

and

alterations

in

cytoskeleton. However, following an injury, EAA concentrations around the injury
site increase to pathogenic levels, leading to drastic increases in Calcium influx
which has the potential of leading to excitotoxic mediated cell death. The most
important organelles involved in the rapid buffering of this Calcium, in order to
avoid neuronal cell damage or death, are the mitochondria, which was discussed
previously in detail.
Mitochondria have low-affinity, high capacity Calcium pumps in their inner
membrane that allow for rapid sequestration of [Ca2+]i. These pumps use
electrochemical gradients generated by the electron transport chain’s (ETC)
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translocation of protons across the inner membrane to build a membrane
potential, ΔΨ. Although the primary usage of ΔΨ is to drive ATP synthesis, it also
allows for electrogenic movement of [Ca2+]i into the mitochondria. As the
mitochondria buffer Calcium, a reduction in ΔΨ occurs. The heightened
intracellular Calcium levels place excessive demand on the mitochondria
sequestering ability eventually resulting in mitochondrial dysfunction that has
been documented for up to 48 hours post-injury [110]. It has been shown that
cortical mitochondria Calcium levels in sham-operated rats range around
~25nmol Calcium/mg. However, after traumatic brain injury, mitochondrial
Calcium levels increase nearly 60% to levels hovering ~40nmol Calcium/mg
[363]. This increase leads to a drastic change to the mitochondrial membrane
potential

eventually

causing

a

detrimental

disruption

to

mitochondrial

homeostasis. Since [Ca2+]i reach pathogenic levels following injury, extreme ΔΨ
reduction occurs and consequently ETC mediated ATP synthesis is hindered
leading to increased ROS production. The dogma is that this ROS can then
oxidize mitochondrial proteins leading to further mitochondrial dysfunction and
the eventual initiation of cell death pathways. However, work Opii et al. found that
even though important proteins, such as PDH, are oxidized, their function is not
loss [343].
As pointed out above, the cascade of posttraumatic mitochondrial ROS
generation and oxygen radical reactions begins in response to rapid elevations in
intracellular Ca2+ immediately following the primary mechanical injury to the
brain or spinal cord with the single electron (e-) reduction of an oxygen molecule
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(O2) to produce superoxide radical (O2•-) which is considered to be a modestly
reactive primordial radical that can potentially react with other molecules to give
rise to much more reactive, and thus more potentially damaging radical species.
The reason that O2•- is only modestly reactive is that it can act as either an
oxidant by stealing an electron from another oxidizable molecule or it can act as
a reductant by which it donates it’s unpaired electron to another radical species
(i.e. an electron-donating antioxidant).
Although O2•- itself is less reactive than •OH radical, its reaction with nitric
oxide (•NO) radical forms the highly reactive oxidizing agent, peroxynitrite (PN,
ONOO-). This reaction (O2•- + •NO → ONOO-) occurs with a very high,
diffusion-limited rate constant. Subsequently, at physiological pH, ONOO- can
either undergo protonation to form peroxynitrous acid (ONOOH) or it can react
with carbon dioxide (CO2) to form nitrosoperoxocarbonate (ONOOCO2). The
ONOOH can break down to form highly reactive nitrogen dioxide(●NO2) and
•OH (ONOOH → •NO2 + •OH). Alternatively, the ONOOCO2 can decompose
into •NO2 and carbonate radical (•CO3) (ONOOCO2 → •NO2 + •CO3).
Increased production of reactive free radicals (i.e. “oxidative stress”) in the
injured brain has been shown to cause “oxidative damage” to cellular (including
mitochondrial) lipids and proteins leading to functional compromise and possibly
cell death in both the microvascular and brain parenchymal cells. The major form
of radical-induced oxidative damage involves oxidative attack on cell membrane
polyunsaturated fatty acids triggering the process of lipid peroxidation (LP) which
has three distinct chemical phases: initiation, propagation and termination. The
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initiation of LP is triggered when a highly reactive (i.e. electron-seeking) oxygen
radical (e.g. ●OH, ●NO2, ●CO3) reacts with membrane polyunsaturated fatty
acids such as arachidonic acid, linoleic acid, eicosapentaenoic acid or
docosahexaenoic acid resulting in disruptions in membrane integrity. Specifically,
initiation of LP begins when a highly “electrophilic” radical steals the hydrogen
electron from an allylic carbon of the peroxidizable polyunsaturated fatty acid.
The allylic carbon is susceptible to free radical attack because it is surrounded by
two relatively electronegative double bonds which tend to pull one the carbon
electron away from the hydrogen electron it is paired with. Consequently, a
reactive free radical has an easy time pulling the hydrogen electron off of the
carbon because the commitment of the carbon electron to staying paired with it
has been weakened by the surrounding double bonds. This reaction results in
the original radical being quenched while the polyunsaturated fatty acid (L),
becomes a lipid radical (L•) due to its having lost an electron.
In the subsequent propagation step, the unstable L• reacts with O2 to form
a lipid peroxyl radical (LOO•). The LOO• in turn abstracts a hydrogen atom from
an adjacent polyunsaturated fatty acid yielding a lipid hydroperoxide (LOOH) and
a second L•, which sets off a series of propagation “chain” reactions. These
propagation reactions are terminated in the third step when the peroxidizable
substrate becomes depleted and/or a lipid radical reacts with another radical or
radical scavenger to yield relatively stable non-radical end products. One of
those end products that is often used to measure LP is the 3 carbon-containing
malondialdehyde (MDA) which is mainly a stable non-toxic compound that when
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measured represents an LP “tombstone”. In contrast, two highly toxic aldehydic
products of LP are 4-hydroxynonenal (4-HNE) or 2-propenal (acrolein) both of
which have been well characterized in experimental brain or spinal cord injury
models [366-368]. These latter two aldehydic LP end products can covalently
bind to basic amino acids (e.g. lysine, histidine, arginine, cysteine) in cellular
proteins, altering their structure and functional properties.
In addition to LP, free radicals can cause various forms of oxidative
protein damage. A major mechanism involves carbonylation by reaction of
various free radicals with susceptible amino acids. Secondly, ●NO2 can nitrate
the 3 position of tyrosine residues in proteins forming 3-nitrotyrosine (3-NT)
which is a specific footprint of PN-induced cellular damage. Similarly, lipid
peroxyl radicals (LOO●) can promote tyrosine nitration by producing initial
oxidation (loss of an electron) which would enhance the ability of ●NO2 to nitrate
the phenyl ring [369]. Multiple commercially available polyclonal and monoclonal
antibodies are available for immunoblot of immunohistochemical measurement of
proteins that have been nitrated by PN. Thus, in summary, LP can cause cellular
damage by destroying the integrity of the phospholipid bilayer as well as
membrane-localized proteins by modification by carbonylation, nitration and/or
binding of aldehydic LP end products such as 4-HNE or acrolein.
Mitochondrial oxidative stress and resulting dysfunction plays an
especially critical role in the post-traumatic cell death cascade in the injured brain
[359, 360, 370, 371] or spinal cord [372, 373]. The initiator of this mitochondrial
homeostatic dysfunction involves a rapidly evolving post-injury intracellular
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accumulation of Ca++ ions which causes the mitochondria to try to buffer
(sequester) the excess Ca++

which in turn causes mitochondrial respiratory

dysfunction and lessened oxidative phosphorylation[354, 359, 370, 371] and
Ca++ buffering capacity [360, 370] and mitochondrial failure due to mitochondrial
permeability transition (MPT) [108, 364]. In addition to the potential activation of
mitochondrial

caspase-dependent

and

caspase-independent

cell

death

cascades, this mitochondrial failure causes a disruption of synaptic function, and
indeed

synaptic

mitochondria

are

more

susceptible

than

non-synaptic

mitochondria [354].
The disruption of respiratory function is preceded by, or at least coincident
with, an increase in mitochondrial free radical production and/or free radicaltriggered LP-mediated oxidative damage [371-373]. Evidence has accumulated
which shows that a particularly important oxidant that is being formed by injured
brain of spinal cord mitochondria is PN [373-378]. The relationship of PN
generation to mitochondrial dysfunction in the injured spinal cord has been
recently documented by studies that have shown that the timing of post-SCI
mitochondrial dysfunction (i.e. respiratory and Ca++ buffering impairment) is
preceded by an increase in PN-induced 4-HNE (i.e. LP), 3-NT (i.e. protein
nitration) and 4-HNE and protein carbonyl content in mitochondrial proteins. Nitric
oxide and a mitochondrial nitric oxide synthase (NOS) isoform (mtNOS) have
been shown to be present in mitochondria [379, 380]. Exposure of mitochondria
to Ca++, which is known to cause them to become dysfunctional, leads to PN
generation which in turn triggers mitochondrial Ca++ release (i.e. limits their
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Ca++ uptake or buffering capacity) [381]. In vitro application of each of the three
PN forms, ONOO-, ONOOH and ONOOCO2, have been found to deplete
mitochondrial antioxidant stores and to cause protein nitration, which is the
hallmark of PN oxidative damage [382]. The loss of mitochondrial function and
the increase in oxidative damage markers, including 3-NT, is antagonized by
early in vivo post-TBI treatment with the PN radical scavenger tempol [376].
Furthermore, exposure of non-injured mitochondria to PN quickly leads to
respiratory dysfunction that is antagonized by tempol pretreatment along with a
reduction in nitration of mitochondrial proteins [383].
Additionally, the neurotoxic LP end products 4-HNE or acrolein are also
able to produce a concentration-related attenuation of the respiratory function of
normal brain or spinal cord mitochondria [384]. In those experiments, acrolein
was observed to be 10x more potent than 4-HNE. Furthermore, spinal cord
mitochondria were found to be significantly more susceptible that brain
mitochondria.

However, scavenging of these carbonyl-containing compounds

with the carbonyl scavenging compound phenelzine has been shown to
attenuate mitochondrial respiratory depression along with a reduction in the
levels of aldehyde-modified mitochondrial proteins [385].
As mitochondria remain in this dysfunctional state due to dysregulation of
Calcium the ETC will reach a point where it can no longer maintain the necessary
ΔΨ needed to allow Complex V to function properly. As the mitochondria remain
in a dysfunctional state with a decreased ΔΨ hovering around 100-120mV, which
is a drastic decrease from the normal membrane potential ranging around
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180mV, the electron transport systems will begin to slow down or even halt. As
discussed in Chapter 1, this change in potential allows for an increase in ROS
production [110]. ANT can then be oxidized resulting in a conformational change
that promotes cypD binding, along with other accessory proteins. VDAC is then
able to bind this protein complex forming the mitochondrial permeability transition
pore, MPTP, which was discussed previously. The MPTP formation exposes the
inner mitochondrial matrix to the cytosol, allowing for the release of apoptotic
initiating factors like Cytochrome C, SMAC/diablo and AIF, which all promote cell
death. Neuroprotective agents that target mitochondrial dynamics and the
membrane permeability pore formation can improve neuronal function in many
disease states and therefore is important to consider when studying Traumatic
Brain Injury.
Pharmacological Treatments for TBI
TBI can lead to drastic cognitive and functional deficits for the injured
person. These deficits can decrease the quality of life for the injured person and
their family as well as place extreme financial burdens on the individuals
involved. To date there is still no FDA approved treatment for this disease;
however, researchers are optimistic that a pharmaceutical intervention can be
found. Scientists interested in finding a cure for TBI are most interested in the
tissue where the the secondary injury cascade occurs following the initial injury.
This is the tissue that is adjacent to the impacted tissue and can undergo a nonmechanical cell death. Due to the neuroinflammation, the generation of free
radicals, the accumulation of other reactive species and sustained mitochondrial
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dysfunction, it is this tissue that is that thought to undergo drastic tissue
dysfunction and cell death through various apoptotic and necrotic cell death
pathways. By minimizing this injury cascade it is believed that the injured party
will experience decreased functional deficits and increased tissue sparing
providing a neural substrate for rehabilitation.
Targeting mitochondrial dysfunction
Some of the most promising neuroprotective agents following TBI are
drugs that target mitochondrial dysfunction. Within the category of mitochondrial
targeting drugs, there are multiple classifications. These include uncouplers,
alternative fuels, antioxidants, oxidative phosphorylation modulators, mPTP
inhibitors and O2 enhancers. Each of these drugs have specific pathways that
are independent of one another and some show synergy when paired together.
When using mitochondrial targeted approached, the time of delivery seems to be
a critical factor. Mitochondrial targeting drugs seem to work best when delivered
within the first hour or two of injury, however some seem to show positive effects
when the therapeutic window is extended even further [110].
One way to avoid mitochondrial dysfunction and the resulting cell death is
by decreasing mitochondrial calcium buffering. Researchers have found that
weak lipophilic acids that act like mitochondrial uncouplers, such as carbonyl
cyanide 4-triflouromethoxy phenylhydrazone (FCCP) and 2,4-dinitrophenol
(DNP), can produce positive therapeutic effects in animal studies of TBI. Acting
as uncouplers are weak lipophilic acids that are able to deplete the membrane
potential and thereby decrease the electromotive force by which calcium enter
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the mitochondria. With decreased calcium uptake, markers of oxidative stress
decreased as well leading to improved cortical sparing of up to 12% and
enhanced cognition measured with the Morris Water Maze test when compared
to vehicle treated animals [350, 363]. Although this technique has shown much
promise, the dose response is steep providing an extra burden if it were to be
used clinically.
TBI induced oxidative stress occurs leading to oxidative modifications on
various proteins rendering them dysfunctional. Oxidative stress with Pyruvate
Dehydrogenase (PDH) has been documented following injury however the
function of PDH does not seem to decrease with this increased oxidation [343].
This leads to the question as to where the mitochondrial dysfunction is
originating. Additionally, glucose mediated depression has been seen in both
animal and humans following TBI which is dependent on the injury severity [386,
387]. Therefore, with metabolic enzymatic dysfunction and decreased metabolic
substrates, a state of acute metabolic crisis has been shown to occur [388].
Alternative biofuels like ketones and beta-Hydroxybutyric acid
(BHB), which are substrates that easily feed into the ETC without the contribution
PDH or GDH, become a promising area of research [389]. For this reason, the
use of ketone bodies in various animal models have been shown to decrease the
production of free radicals through increases in glutathione production as well as
increase the expression of various endogenous mitochondrial uncoupling
proteins [361, 389, 390]. A study from Davis et. al. showed that with a moderate
contusion injury in rats, treatment with D-beta-hydroxybuterate can decrease
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markers of oxidative stress and increase mitochondrial oxidative phosphorylation
following injury [361]. With these marked improved mitochondrial bioenergetics,
cortical sparing and functional recovery has been seen as well. [391, 392].
Another important secondary injury mechanism that seems to show
therapeutic effects when targeted following a TBI are those which up-regulate
endogenous antioxidant activities. As mentioned previously, GSH/Glutathione is
an endogenous antioxidant which is located in the mitochondria and converts the
H2O2 generated by mnSOD to H2O. Present at mM levels, it is known to be the
most abundant antioxidant found within the cell. Previous reports have shown
that targeting GSH using a modified molecule of gamma-glutamylcysteine
reduces markers of oxidative damage following TBI [393, 394]. Similarly, studies
have also shown that n-acetyl cysteine, NAC, administration, the non-amide form
of NACA, can increase brain GSH levels, improve mitochondrial function, reduce
BBB permeability, and decrease brain edema following TBI [395-397]. NAC has
also been shown to be effective in reducing free radical dependent
cerebrovascular responsiveness in fluid percussion model of TBI which are likely
the result of NAC’s ability to improve free radical scavenging mechanisms [398400]. Additionally, NAC has also been shown to be an effective compound in CCI
by inhibiting cerebral inflammatory responses [401] and, when used in
combination with minocycline, it has been shown to improve cognition and
memory function following TBI [402, 403]. Most recently, NAC treatment has
been evaluated in U.S. service members deployed to Iraq who had been
exposed to a blast induced mild traumatic brain injury (mTBI). The initial report
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indicates significantly improved behavioral outcome measures when patients
were treated with NAC for 7 days compared to the placebo treatment [398, 404].
The Authors reported that if NAC treatment were received within 24 hrs of blast
injury, members had significantly better chances of symptom resolution which
included dizziness, hearing loss, headache, memory loss, sleep disturbances,
and neurocognitive dysfunction. However, given the limited CNS bioavailability of
NAC due to its limited BBB, cellular and, most importantly, mitochondrial
permeability, the potential benefit of GSH as a therapeutic target has most likely
been underestimated and has not reached its full potential. This justifies the
foundation for a clinical trial that is currently underway to utilize the membrane
transporter inhibitor probenecid to improve bioavailability of NAC following TBI in
pediatric patients (Pro-Nac clinical trial, ClinicalTrials.gov ID NCT1322009).
Building upon this, researchers have now started to investigate the use of
NACA, the novel amide form of NAC which has increased bioavailability and
ability to cross cellular and mitochondrial membranes. NAC is negatively charged
at physiological pH, and mostly lipid insoluble in vivo, whereas the chemical
derivative NACA is neutral and has high lipid solubility under physiological
conditions [405, 406]. Although the literature on NACA is still somewhat limited it
has been shown to increase tissue sparing and functional recovery following a
CNS injury when compared to NAC and vehicle treated animals. These results
were seen in both models of TBI and Spinal Cord Injury and have been attributed
to the increased mitochondrial function and decreased oxidative stress which
were both observed [344, 407-409].
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Interventions with multiple targets
Lastly, it is thought that due to the complicated nature of the secondary
injury cascade, the best pharmaceutical interventions will target multiple steps in
this cascade. Cyclosporin A, CSA, is a drug that has been investigated for the
use for a use in TBI and has shown great promise. CSA had multiple indications,
including immune suppression, inhibition of mPTP formation and indirect
antioxidant properties. In its action of targeting mPTP, CSA binds Cyclophilin D,
CypD. Once CSA binds CypD, it is not able to contribute to the structure of the
megapore leading to non-functionality thus preventing Calcium overload induced
MPT. As an indirect antioxidant, CSA is not able to directly scavenger reactive
radicals or aldehydes. Rather, CSA inhibition of MPT in TBI models secondarily
lessens mitochondrial free radical formation and decreases the further
accumulation of 4-HNE and 3-NT together with a histological neuroprotection in
terms of decreased lesion volume with a therapeutic window as long as 8 hours
[110, 360, 410-413]. This effect is totally unrelated to immunosuppression since
the non-immunosuppressive cyclosporin A analog, NIM811, is able to duplicate
the posttraumatic mitochondrial and neuroprotective effects [410, 414]. A phase
2 dose escalation and safety study in 40 severe TBI patients has suggested that
CSA treatment initiated within the first 8 hours and continued for 3 days may
improve their functional recovery [415]. However, additional clinical trials are
needed to determine the reliability of this effect.
Portions of this chapter have been previously published in:
Yonutas HM, Hall ED, Sullivan PG; The Functions, Disease-Related
Dysfunctions, and Therapeutic Targeting of Neuronal Mitochondria. Gribkoff VK,
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Jonas EA, Hardwick J, editors. United States: Wiley; 2015. Therapeutic Targeting
of Neuronal Mitochondria in Brain Injury; 400p
and
Yonutas HM, Head E, Sullivan PG; Foods and Dietary Supplements in the
Prevention and Treatment of Disease in Older Adults. Watson RR, editor.
Boston, MA, USA: Elsevier; 2015. Chapter 8, Targeting Mitochondria for Healthy
Brain Aging; p.71-83. 380p.
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CHAPTER 4: PIOGLITAZONE AS A TARGET FOR TBI INDUCED
MITOCHONDRIAL DYSFUNCTION
Traumatic brain injury (TBI) is a serious healthcare problem resulting in
health, emotional, behavioral and financial complications [315]. The discovery of
effective pharmacological agents is necessary to help this ailing population. Alas,
there are no approved pharmacological treatments for TBI so progress in this
area is vital. Appropriately aligned, this study will investigate the mechanism of
neuroprotection offered by pioglitazone, an FDA approved pharmacological
agent, and the importance of mitoNEET within this mechanism. This study will
also help advance the field of traumatic brain injury by investigating the
importance of mitochondrial bioenergetics to neuronal loss following TBI, while
possibly uncovering a novel neuroprotective therapeutic target, mitoNEET.
Complications that arise from TBI are multifaceted and originate from a
mechanical insult. This insult leads to tearing of blood vessels, axonal shearing
and cellular death, resulting in increased membrane permeability and the
initiation of multiple signaling cascades [325]. Since the initial insult cannot be
reversed, it is this secondary injury cascade where drug interventions can be
targeted and advantageous. Some well accepted occurrences in the secondary
injury cascade are alterations in excitatory amino acids (EAA) [309, 355],
disruption of Calcium homeostasis [350, 359, 416], and mitochondrial dysfunction
[108, 110, 313, 346, 347, 354, 359-361, 364, 416-420]. The implications of
abnormally high excitatory amino acids, EAA, levels around the site of the injury
are generally accepted. These EAAs activate multiple receptors and channels,
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such as the NMDA receptor [421, 422]. Activation of these receptors leads to
Calcium influx into neurons. At low to moderate levels, this intracellular Calcium
concentration, [Ca2+]i, is used as a potent signaling molecule; however, following
an injury, EAA concentrations drastically elevate Calcium levels leading to an
overwhelming influx of Calcium and consequential neuronal cell death [423]. One
of the most important organelles involved in the rapid buffering of this Calcium is
the mitochondria.
Mitochondria and TBI Link: Mitochondria have low-affinity, high capacity
Calcium uniporters in their inner membrane that allow for rapid sequestration of
[Ca2+]i. These uniporters “piggyback” off the membrane potential, ΔΨ, generated
by the electron transport chain’s (ETC) translocation of protons across the inner
membrane. As the mitochondria buffer Calcium, a reduction in ΔΨ occurs.
Following injury, [Ca2+]i rapidly increases and mitochondria work feverishly to
buffer it leading to decreased ΔΨ and decreased ETC mediated ATP synthesis.
This mechanism continues until ΔΨ is depleted. At this point, mitochondria
become dysfunctional and cell death pathways are initiated. Mitochondrial
dysfunction related to excitotoxicity may be a therapeutic target for future drug
interventions. Following a CNS (central nervous system) injury excitotoxic event,
mitochondrial uncouplers have been studied to inhibit mitochondrial Calcium
uptake through the reduction of ΔΨ. These uncouplers have been shown to be
neuroprotective due to their ability to modulate mitochondrial dysfunction [350,
363, 420, 424]. Recent studies have also shown that post-injury treatment of
pioglitazone is able to attenuate mitochondrial dysfunction and increase cortical
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sparing, however the exact target of pioglitazone within this mechanism is still
unknown.
PPAR, PPAR agonists and TBI: Peroxisome Proliferator Activated
Receptors (PPARs) are Nuclear Receptor proteins that can heterodimerize in a
ligand-dependent and -independent manner to regulate gene expression of
multiple molecular processes. There has been 3 PPARs identified including α, δ/
β or and γ [425-429]. PPAR-γ the most widely studied subtype in the area of
CNS injury due to its well-established role in the regulation of adipogenesis,
glucose homeostasis, cellular differentiation, apoptosis and modulation of
inflammation resulting from chronic and acute neurological insult. One class of
drugs which have shown much promise as neuroprotective agents are
thiazolidinedione which are anti-diabetic drugs used for the treatment of type 2
diabetes. This class of drugs were generated for their ability to activate various
Peroxisome Proliferating Activating Receptor isoforms [427, 428]. One of the
isoforms in this class of drugs that has drawn much attention due to its ability to
provide neuroprotection in models of CNS injury is pioglitazone [347, 430].
Originally, the mechanism of neuroprotection for this drug was thought to be
through the modulation of PPARγ, however recent data analyzing PPARγ
activation, as well as pioglitazone binding affinities for a specific mitochondrial
membrane protein, may prove that this initial hypothesis needs reconsideration.
Data has suggested that the therapeutic effects of pioglitazone may be more
complex than just activation of PPAR. Not only has pioglitazone been shown to
decrease inflammation it has also been shown to decrease oxidative damage,
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attenuate mitochondrial dysfunction and reduce cell death following CNS injury,
pathways which seem to be slightly more encompassing and on a quicker
timeline than what could be attributed solely as PPARγ activation [311, 347, 430,
431]. To further support this, a study by Thai et al. used PPAR antagonists to
show that the neuroprotective effects seen with pioglitazone were independent of
PPARγ. Additionally, a study by Bieganski et. al. showed that pioglitazone bound
to mitoNEET, a mitochondrial membrane protein with an unknown role in the cell
[432]. Lasly, a recent study by Zuris et al. showed that pioglitazone binding to
mitoNEET was able to inhibit [2Fe2S] cluster transfer upon binding however the
role of such a mechanism in providing therapy in CNS injury is unknown [433].
The combination of this data has stemmed ample research from our lab showing
that pioglitazone is unable to increase mitochondrial bioenergetics in transgenic
mice who lack mitoNEET and that pioglitazone loses some of its neuroprotection
following injury in these animals as well.
mitoNEET: mitoNEET was discovered in 2004 by Colca et. al. in the brain,
liver and skeletal muscles of rodents [434]. This discovery was a result of a
pioglitazone pull-down assay that bound to the novel m-17 kDa mitochondrial
membrane protein, which was later termed mitoNEET [434]. The exact role of
mitoNEET still remains unclear. However, it is known that mitoNEET knockout
mice experience reduced oxidative capacity hinting to an importance in
mitochondrial mediated respiration [435, 436]. A recent publication also found
that mitoNEET binds Glutamate Dehydrogenase I allowing for direct control over
the Krebs cycle and therefore control over mitochondrial respiration [83].
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Therefore, I propose mitoNEET to be important for mitochondrial homeostasis
and

therefore

a

crucial

therapeutic

target

for

pioglitazone

mediated

neuroprotection.
Results
Pioglitazone is able to increase mitochondrial respiration in a biphasic
manner following calcium insult.
The mitochondrial effects of pioglitazone have been debated in the
literature [347, 430, 437]. Pioglitazone has been shown to interact with multiple
proteins at the cytosolic, nuclear and mitochondrial level [431, 432, 434, 437,
438]. In order to study the importance of mitochondria bioenergetics in
pioglitazone mediated neuroprotection, we isolated mitochondria, removing any
interactions due to cytosolic or nuclear proteins such as the PPARs. This allows
for insight into what exactly is occurring in the mitochondrial level. Previous
results from Murphy et. al. have shown that micromolar concentrations of
pioglitazone are able to decrease mitochondrial respiration [437]. However,
results from Sauerbeck et al show that lower concentrations, nanomolar to
micromolar range, of pioglitazone can increase mitochondrial respiration in
isolated mitochondria [347]. In order to determine where this discrepancy arose,
cortical mitochondria were isolated from naive CD57/BL6 mice, insulted with
Calcium (150nm/mg) and then treated with various concentrations of
pioglitazone. Mitochondrial bioenergetics were analyzed (Figure 4.1). This
calcium insult provides a similar effect to that seen within the excitotoxicity
mechanism following a TBI. 50nM pioglitazone was able to increase
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mitochondrial respiration 12.7% compared to naïve non-insulted mitochondria
and 32.8% compared to vehicle treated calcium insulted mitochondria. Also, a
biphasic effect was seen where lower dosages of pioglitazone (0.05uM) provided
increased mitochondrial bioenergetics and higher concentrations provided
decreased mitochondrial bioenergetics. This data supports what has been
published in the literature where lower concentrations of pioglitazone increased
mitochondrial respiration and higher concentrations decreased mitochondrial
respiration.
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Naïve
with
No
Calcium

Figure 4.1 Pioglitazone Dose Response: Pioglitazone is able to increase state
V mediated maximal mitochondrial respiration in isolated from wild-type C57BL/6
mice cortex insulted with 150nm/mg of calcium. One-way ANOVA, Compared
Drug Treated to Ca + Vehicle, Bonferroni Post-Hoc – protects from a type I
error (Detecting an effect that is not present), N=3, SEM
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Pioglitazone loses its neuroprotective effects in mitoNEET KO animals.
As mentioned previously, mitoNEET is a novel mitochondrial membrane
protein which has been shown to modulate mitochondrial respiration.
Pioglitazone has also been shown to bind mitoNEET however the importance of
this interaction in pioglitazone’s neuroprotective effects remains unknown.
Therefore, we wanted to preform a similar test to what was performed in
mitochondria isolated from wild-type mice however use mitoNEET null mice
instead. The mitoNEET null mice were generated by Dr. Stewart Ross at the
university of Kentucky and used previously Western blot was performed in WT
versus mitoNEET null cortical homogenate to confirm the presence, or lack, of
mitoNEET [435] (Figure 4.2). As shown in figure 1, calcium is able to decrease
mitochondrial respiration in wild-type mitochondria and pioglitazone is able to
reverse these inhibitory effect. However, in mitochondria isolated from the
cortical tissue of mitoNEET null mice, calcium (150nm/mg of protein) had little
effect on mitochondrial respiration and the use of pioglitazone provided no
increased respiration (Figure 4.3). In order to further understand this
phenomenon, we evaluated the membrane potential using TMRE and Ca5
indicators and there was no differences observered, data not shown. Combined,
these results show that mitoNEET is important in calcium mediated decreases in
mitochondrial bioenergetics and that mitoNEET is necessary for pioglitazone
mediated increased respiration following an insult from Calcium.
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KO

WT

KO

WT

Figure 4.2 WT versus mitoNEET null protein expression: Western blot
analysis of mitoNEET expression in WT versus mitoNEET null animals.
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Naïve with
No Calcium

Figure 4.3 Pioglitazone dose response in mitoNEET null mice: In
mitochondria isolated from the cortical tissue of mitoNEET null mice, calcium
insult (150nm/mg protein) has no significant effect and pioglitazone is unable to
increase state V mediated maximal mitochondrial respiration. One-way ANOVA,
Compared Drug Treated to Ca + Vehicle, Bonferroni Post-Hoc, N=3, SEM
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Work from Sullivan et. al. and many others have shown that mitochondrial
dysfunction is progressive over the first 24 to 48hrs following a control cortical
impact and that amelioration of this mitochondrial dysfunction can improve
neurological function and cortical sparing. This mitochondrial dysfunction can be
targeted with various therapeutic interventions in order to improve tissue and
functional outcomes following an injury. Pioglitazone is one drug that has been
shown to both target mitochondrial dysfunction and improve tissue and functional
outcome. However, the question that arises when studying pioglitazone mediated
neuroprotection following a traumatic brain injury is ‘what is its mechanism?’.
This is a difficult question to answer because pioglitazone has been shown to
interact with multiple proteins within the cell. In the past, much interest has been
placed on pioglitazone interaction with various isoforms of PPAR however one
specific protein that is starting to gain some interest in the literature is mitoNEET.
This protein is found within the mitochondria giving it direct localization to
improve mitochondrial bioenergetics. In order to test the importance of mitoNEET
in pioglitazone’s ability to increase mitochondrial bioenergetics following injury,
mitoNEET null and wild-type mice were injured and received one IP injection of
pioglitazone at 12 hours post-injury. The animals were sacrificed and cortical
mitochondria were isolated at 13 hours post-injury. Mitochondria isolated from
mice treated with pioglitazone had a 54% increase in mitochondrial bioenergetics
compared to vehicle treated wild-type mice. On the contrary, mitoNEET knockout
mice experienced no increase in mitochondrial bioenergetics compared to
vehicle treated animals of the same genotype. This data provides support that
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the ability of pioglitazone to improve mitochondrial dysfunction following
traumatic brain injury is directly dependent on the presence of mitoNEET.
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Figure 4.4 Pioglitazone response in WT verus mitoNEET Null mice: FCCP
mediated, maximal mitochondrial oxygen consumption rate, in wild-type and
mitoNEET null mice (n=3) who received pioglitazone (1 IP injection, 10mg/kg) at
12hours post-injury with isolations at 13hours post-injury. Mitochondria from wildtype mice treated with pioglitazone had significantly increased bioenergetics
compared to mitoNEET null mice. Data represents means + SEM, *p=0.0322
wild-type compared to mitoNEET null mice.
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Pioglitazone treatment following TBI is able to increase cortical sparing
however the effect is diminished when mitoNEET is removed.
As mentioned previously, research has found that pioglitazone is able to
alter mitochondrial bioenergetics and improve neuroprotection [347, 430]. Many
pharmacological treatments that target mitochondrial dysfunction have also
shown promising neuroprotective effects following an injury to the CNS [361,
439-444]. To test whether the change in mitochondrial bioenergetics lead to
increased cortical sparing following a brain injury, adult wild-type and mitoNEET
null mice (n=6) received a moderate contusion injury and then received either
vehicle (DMSO) or 10mg/kg of pioglitazone through IP injection at 15min and
then daily for the first 7 days post-injury. Cortical tissue sparing was accessed at
14 days post-injury and pioglitazone was found to be neuroprotective following
TBI in wild-type (+/+) but not mitoNEET null (-/-) mice (n=6, p=0.0049). As shown
in Figure 3, pioglitazone treatment significantly increases tissue sparing in wildtype (+/+) mice but this effect was lost in mitoNEET null (-/-) mice. The effects of
pioglitazone that are seen in the mitoNEET mice are likely due to other
neuroprotective effects mediated at the cytosolic and/or nuclear level. It is also
important to note that no significant differences were measured between vehicletreated animals of either genotype, showing that the removal of mitoNEET from
the mitochondrial membrane did not increase the animals’ susceptibility to injury.
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Figure 4.5: Pioglitazone is neuroprotective following TBI in wild-type (+/+)
but not mitoNEET null (-/-).
In this study, mice (n=6 per group) were injured (1.0 mm, severe) followed by
pioglitazone injections (10mg/kg) at 15min, and 24hours post injury with cortical
tissue sparing was assessed at 7 days. Pioglitazone treatment significantly
increases tissue sparing in wild-type (+/+) but not mitoNEET null (-/-) mice.
Additionally, no significant differences were measured between vehicle treated
animals of any genotype. One-way ANOVA, Compared Drug Treated to
Vehicle within same genotype, Bonferroni Post-Hoc, n=6, p=0.0049, mean
+/- SEM
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mitoNEET binding with a mitoNEET specific ligand, NL-1, increases cortical
sparing and improves functional outcome following a TBI.
Due to the slight trend of neuroprotection seen in mitoNEET null mice who
were treated with pioglitazone, we decided to probe the importance of targeting
mitoNEET specifically, with a mitoNEET ligand. In regards to this non-significant,
off-target effect seen with pioglitazone, it is likely due to interactions at the
cytosolic level, quit possibly with PPAR. We know that this effect is due to
cytosolic contributions because we do not see increases in isolated mitochondrial
respiration in mitoNEET KO mitochondria however do see an effect in wild-type
mitochondria. Therefore, we moved our studies forward hypothesizing that NL-1
would provide the same degree of neuroprotection which was seen with
pioglitazone, however render no trends towards neuroprotection in the mitoNEET
null mitochondria. Therefore, collaborators synthesized a compound that binds to
mitoNEET called NL-1. Pharmacodynamic studies have shown that this drug is
very similar to pioglitazone, retaining the traditional glitazones structure, binding
to mitoNEET with equal affinity as pioglitazone, however lacks the PPAR binding
region. Following a severe injury, either WT or mitoNEET null mice received
either an IP injection of 10mg/kg NL-1 or vehicle (DMSO) at 15 minutes and then
daily for the first 7 days post-injury. At 7 days post-injury, animals were sacrificed
and tissue sparing was calculated. As seen in Figure 4.6, NL-1 administration
following injury significantly increases (p=0.033, n=16) cortical sparing by 37%
compared to vehicle treated animals.
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Figure 4.6: NL-1 administration increases cortical tissue sparing after TBI.
CD57bl6 WT or mitoNEET null mice received the mitoNEET ligand, NL-1, (n=16,
IP injection, 10mg/kg, at 15min and then daily for the first 7 days post-injury)
following a moderate injury (1.0mm) had a significant increase in cortical sparing
at 37% compared to vehicle treated mice (n =16) at 7 days, an effect that was
lost in the mitoNEET null animals. One-way ANOVA, Compared Drug Treated
to Vehicle within same genotype, Bonferroni Post-Hoc, n=16, p=0.0222,
mean +/- SEM
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WT Animals

KO Animals

Vehicle

NL-1

Figure 4.7 Qualitative Images of NL-1 Cortical Sparing: Representative
figures of the cortical sparing seen in WT animals treated with NL-1 compared to
either vehicle treated or drug treated without mitoNEET’s presence.
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The neuroprotective effects seen with NL-1 lead us to believe that
treatment with NL-1 could also increase functional recovery following injury. With
the model of injury used in this study, animals experience damage to regions of
the motor cortex leading to motor deficits. To test these deficits, animals are
trained before their TBI surgery to traverse various sized beams. Following injury,
the animals are then placed on the various sized beams and foot faults are
measured as an indication of deficits to the corticospinal tracts. Therefore, the
animals were trained to traverse the beams and then provided a severe injury to
both wild-type and mitoNEET null mice. We treated them with either vehicle or
10mg/kg of NL-1 at 15 minutes’ post-injury and then daily for the first 7 days.
Foot faults on the beam were tested at 1 hour, 1 day, 3 days and 5 days postinjury. Injections on behavioral test days were provided following the behavioral
tests in order to avoid any confounding stresses. The wild-type mice treated with
NL-1 had a significant increase in functional recovery at day 5 compared to
vehicle treated, which is an effect that was not seen in the mitoNEET null mice.
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Figure 4.8: Wild-type mice treated with NL-1 had a significant increase in
functional recovery, an effect lost in the mitoNEET null mice. Wild-type and
mitoNEET null mice were trained on the beam walk test and then received a
severe CCI injury 24 hours later. They were given 8 IP injections of 10mg/kg of
NL-1 at 15 minutes and then every 24 hours thereafter for the first 7 days postinjury. At 1 hours, 1day, 3 days and 5 days post-injury, the beam walk test was
performed and foot faults were measured. Wild-type mice treated with NL-1 had
improved performance on this test compared to vehicle treated mice. This effect
was lost in mitoNEET null mice. Two-way ANOVA, Compared Drug Treated to
Vehicle within same genotype, Bonferroni Post-Hoc, n=16, p=0.0168, mean
+/- SEM
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mitoNEET is able to interact with GDH providing insight to a possible
neuroprotective mechanism.
Following a brain injury, a dysregulation of excitatory amino acids occurs,
specifically related to Glutamate. This eventually leads to the initiation of
excitotoxicity through pathogenic influxes of calcium. Mitochondria are the first
line of defense in order to rapidly buffer high intracellular calcium levels. As they
continue to buffer Calcium in a process mediated by the mitochondrial calcium
uniporter, the membrane potential, generated by the electron transport chain,
becomes depleted. The current theory is that as Calcium levels reach high
enough level, reactive oxygen species and reactive nitrogen species (ROS and
RNS specifically) production increases leading to the damage of proteins within
the mitochondria. However, work published by Pandya, show that with increased
calcium insult in isolated mitochondria did not lead to increased oxidative stress.
Additionally, calcium insult leads to decreased state III respiration, which hints to
an inhibition that is mediated either at Complex I or upstream. According to this
2013 paper however, neither Complex I nor PDH activity were inhibited by
calcium load hinting at another possible mechanism [362]. After observing
decreased calcium inhibited respiration in the mitoNEET null mice, we became
interested in a possible mechanism. Work from Roberts observed that mitoNEET
was able to interact with GDH, which was observed during a pull-down assay
[83]. Additionally, work from Cole found that GDH expression increases following
TBI, which was proposed to be due to a lack of BCAA [445]. However, I
hypothesize that decreased mitoNEET activity leads to inhibition of GDH
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following TBI, which leads to compensatory increased expression. I propose that
this effect would be reversed following treatment with either NL-1 or pioglitazone.
Discussion
The mechanism of pioglitazone mediated neuroprotection has been highly
debated for years. Historically, the effect of this glitazones has been thought to
be through its interactions with PPAR-γ. However, many research groups have
found pioglitazone retains its therapeutic effects in the presence of PPAR
inhibitors. Additionally, researchers have found that pioglitazone is able to target
mitochondrial bioenergetics and we have found that it can increase mitochondrial
bioenergetics in pure isolated mitochondria, removing any effect from the cytosol
or nucleus. Therefore, with this study, we attempted to understand the
importance of mitoNEET within the mechanism of neuroprotection provided by
pioglitazone following a control cortical impact injury.
One topic that has been highly debated regarding pioglitazone is whether
it increases or decreased mitochondrial bioenergetics. In a previous study
completed my Murphy et. al. mitochondrial bioenergetics were decreased with
permeabilized

cells

were

incubated

with

micromolar

concentrations

of

pioglitazone [437]. However, research from Sauerbeck et. al. found that
pioglitazone is able to increase mitochondrial bioenergetics when isolated
mitochondria were incubated with nanomolar concentrations of pioglitazone
[347]. Results from this study provide possible insight into where this discrepancy
may be arising in that pioglitazone has a biphasic effect which increased
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mitochondrial bioenergetics at low concentrations but can become toxic to
mitochondria when concentrations become too high.
Building upon the importance of dosage when working with pioglitazone,
the next important topic to discuss is the mechanism of neuroprotection. In the
literature, pioglitazone is described as a PPAR agonist that provides
neuroprotection through changes in gene expression of a plethora of important
proteins such a cytokines and various endogenous antioxidants. These changes
are extremely important when treating traumatic brain injury and should not be
disregarded. However, interestingly enough, the improvements of mitochondrial
dysfunction that have been seen following an injury to the brain occur on a
timescale much more rapid than the effects seen with changes in gene
expression. As seen with the previous data, animals treated with pioglitazone at
12 hours post-injury and sacrificed 1 hour later had increased mitochondrial
function compared to vehicle treated animals. Since the drug was only introduced
one hour before the mitochondria were isolated, the effects are thought to be
based on direct interactions and not through changes in gene expression.
This observation raises the question, if pioglitazone is not providing
neuroprotection through changes in gene expression, then what is pioglitazone
interacting with directly? From this study it seems as if the answer to this
question lies within mitoNEET. From the data we see that pioglitazone is able to
increase mitochondrial bioenergetics by over 54% in wild-type mice who express
mitoNEET in their mitochondria however lose its ability to increase mitochondrial
bioenergetics in mitoNEET null (-/-) mice. To further support this, wild-type mice
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that were injured with a moderate CCI injury had a 64% increase in tissue
sparing compared to mitoNEET null (-/-) mice. This provides evidence that
mitoNEET is crucial for pioglitazone mediated neuroprotection.
In order to further test that hypothesis that binding mitoNEET with a
mitoNEET ligand is indeed able to increase mitochondrial bioenergetics, NL-1
was synthesized as a truncated glitazones, retaining a structure similar to
pioglitazone which allows it to bind mitoNEET but not interact with the PPAR
isoforms. This drug was not only found to provide a 37% increase in cortical
sparing but was able to improved motor function in wild-type mice, which was not
seen in mitoNEET null (-/-) mice.
The data provided from this study provides strong evidence that
pioglitazone mediated neuroprotection following a contusion injury in rodent
models is able to provide increase tissue sparing and improved functional
outcome is dependent on interactions with mitoNEET. This data also supports
mitoNEET as a potential therapeutic target for brain injury as well as other
neurodegenerative diseases where mitochondrial dysfunction is prevalent.

Copyright © Heather Marie Yonutas 2016
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CHAPTER 5: METHODS USED FOR THESIS WORK

Animals: All of the studies performed were approved by the University of
Kentucky Institutional Animal Care and Usage Committee. All experiments were
conducted using either adult (male Sprague-Dawley rats (Harlan, Indianapolis,
IN) weighing 300-350g (chapter 2) or adult (~8-10 week old) male and females
adult wild-type (C57BL/6) or mitoNEET null mice with an average mass of 30
grams. Studies with wild-type (WT) and mitoNEET -/- (KO) mice were the same
mice described in [435] which are bred and housed in the SCoBIRC transgenic
animal core. The rats were housed 3 per cage and the mice were house 5 per
cage. Both sets of animals were maintained in a 12-hr light/12hr dark cycle and
fed a balanced diet ad libitum.

mitoNEET Null Colony: Genotyping of these animals has been done by our
laboratory and wild-type littermates will be used as controls. These animals have
been backcrossed into the C57BL/6 strain of mice (minimum of 30 generations)
to account for differential strain sensitivity to neuronal insult and injury. C57BL/6
mice are an inbred strain, maintained in a barrier-reared environment, widely
used in TBI research and as genetic background strains in transgenic models.

Controlled Cortical Impact Brain Injury: All surgical procedures were
performed as previously described [110, 346, 350, 354, 361, 363, 364, 416, 418,
444] and were classified as severe (1.0 mm (mice) deep contusion at 3.5
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meters/second for 500ms). Prior to injury, animals were anesthetized using 2%
isofluorane, weighed and their head was shaved to remove hair at the site of the
surgery. Animals were then placed in a Kopf stereotaxic frame (David Kopf
Instruments, Tujunga, CA) for proper positioning under a pneumatic head
impactor (Precision Science Instruments) and body temperature was maintained
at 37oC with the use of a isothermal pad. A 5mm craniotomy was drilled lateral to
the central fissure on the left side of the skull centered between lambda and
bregma, with much care taken to not disrupt the dura. Injury groups then
received a unilateral injury directly to the surface of the brain. Sham animals
received a 5.0mm craniotomy but did not receive an impact to the brain.
Following the injury, a hardened circular piece of dental acrylic made the night
before, and secured with sterile surgical adhesive over the craniotomy. The
incision was then closed with medical grade sutures.
After the surgery sites were closed on all animals, the isofluorane was
shut off and the animals were removed from the stereotaxic frame. They were
then placed in a clean cage that was temperature controlled at 37oC with a
heating pad until the animals were mobile and fully responsive.
To investigate the neuroprotective effects of either pioglitazone or NL-1
after TBI, animals were given a CCI in the manner described above and then
given an IP injection of either pioglitazone or NL-1. Both drugs were solubilized in
vehicle (100% Ethanol, 1uL 38% HCl, and 25uL of 0.9% saline for pioglitazone
and 100% DMSO for NL-1) before injection. All drugs were made at an
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appropriate concentration in order to inject ~100uL per animals and exact
adjustments for weight were made before the injection was given.

TABLE 5.1 Dosage Paradigm for Animals
Desired Dosage For Animal

Concentration of Drug

1mg/kg

0.3mg/ml

10mg/kg

3mg/ml

20mg/kg

6mg/ml

40mg/kg

12mg/ml
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Mitochondrial isolation: Mitochondria were isolated using previously employed
differential mitochondrial isolation methods [347, 362, 446]. Animals were
sacrificed by asphyxiation with CO2 and then rapidly decapitated. This CO2
asphyxiation method is the standard euthanasia method used. The animal’s
consciousness is quickly removed allowing for the rapid removal of the brain
without any confounding factors that other methods would pose, such as the use
of FatalPlus. The brain is then washed with ice-cold (around 4oC) mitochondrial
isolation buffer with EGTA (MIB+EGTA) made-up of 215 mM Mannitol, 75 mM
Sucrose, 0.1% BSA, 1 mM EGTA, and 20 mM HEPES at pH 7.2. This step
removes excess blood and debris, while chilling the brain rapidly. The used of
MIB+ETGA at this point is a crucial step as EGTA is used to chelate free calcium
released during the homogenization process. Cortical tissue, either total or a
5mm punch if the brains were injured, were then homogenized in a PotterElvejhem manual homogenizer with 3mL of MIB+EGTA. Once the tissue was
fully homogenized, the samples were spun via centrifugation at 1300 × G for
3 min.
Following the last spin, the supernatant is placed in a fresh tube and the
pellet is re-suspended in MIB+EGTA. The samples are then spun again at
1300 × G for 3 min. This step allows for the separation of heavy cellular debris
such as the plasma membrane, from smaller intercellular organelles, etc. The
supernatant from the first and second spins were collected in separate tubes and
spun at 13,000 × G for 10 min. This spin allows for the removal of light-weight
objects such as proteins, RNA, etc. The pellets from both tubes are then
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combined, resuspended in 500 μl MIB+EGTA and placed in a nitrogen bomb at
1,200 psi for 10 min. The pressure in the nitrogen bomb is rapidly released after
10 min in order to pop the synaptosomes and release synaptic mitochondria.
The samples are then placed as the top layer on a Ficoll separation
column which consisted of a 10% Ficoll layer (bottom) and a 7.5% Ficoll layer
(top). The Ficoll column with sample carefully placed on top is centrifuged at
32,000 × G for 30 min at 4 °C. Following the Ficoll purification, the mitochondrial
pellet, bottom layer, is re-suspended in mitochondrial isolation buffer without
EGTA (MIB-EGTA) and centrifuged at 10,000 × G for 10 min at 4 °C in order to
remove residual Ficoll and EGTA from the purified mitochondrial sample. The
final mitochondrial pellet is re-suspended in MIB-EGTA to yield a final
concentration of approximately 10 mg/ml. These samples are stored immediately
on ice. Protein concentrations for each sample is determined with all the samples
on the same plate using the BCA protein assay kit and measuring absorbance at
560 nm with a Biotek Synergy HT plate reader (Winooski, VT).
Measurement of mitochondrial bioenergetics: Oxytherm
As mentioned in Chapter 1, and seen in Figures 1.10 and 1.11, the
Oxytherm which uses a Clark Electrode, is historically used for mitochondrial
bioenergetics assays. Before the mitochondrial samples are evaluated, the
electrode is built in the manner described in Chapter 1. The Oxytherm is then
calibrated at 37oC, measuring 100% oxygen, 0% oxygen in the presence of
Sodium Borohydride (Sigma 213462-25G) and then 100% oxygen again. Once
calibrated, 250uL of Respiration Buffer (RB) composed of 215 mM mannitol,
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75 mM sucrose, 0.1% BSA, 20 mM HEPES, 2 mM MgCl, 2.5 mM KH2PO4 at
pH 7.2, is added to the chamber along with 50ug of mitochondrial protein and the
Oxytherm program, Oxy32, is started to read oxygen changes.
Substrates and inhibitors are then added allowing us insight into the
functionality of the proteins within the Electron Transport System.
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TABLE 5.2 Mitochondrial Bioenergetics Overview
Targeted
Substrate or
Amount
Rational of
State of
Concentration
Inhibitor Added
Added
Addition
Respiration
State I
Mitochondria
~5ul
10ug/ul
No Substrate
added
State II
Pyruvate/Malate
2.5ul
5mM/2.5mM
Added to “charge”
the membrane.
Pyr and Mal will
start the Krebs
Cycle allowing for
the production of
NADH. These are
then fed into the
ETS, building the
proton-motive
force however
this force cannot
be converted into
energy (ATP) due
to a lack of ADP.
State IIIADP
ADP
1.25ul x 2
150uM
The presence of
ADP allows ATP
Synthase to
convert the
proton-motive
force (Membrane
Potential) built by
the addition of
Pyr/Mal into ATP.
With differential
mitochondria,
ATPases will use
the ATP as it is
generated leading
to a depletion of
Oxygen. In
isolated
mitochondria, the
ATP synthase will
convert all the
ADP to ATP and
the oxygen
consumption will
plateau. A second
amount of ADP is
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State IV

Oligomycin

0.5ul

1uM

State V

FCCP
/Uncoupler

0.5ul

1uM

State
VSuccinate

Rotenone +
Succiate

0.1ul +
5ul

1mM + 10mM
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added again in
order to get
maximal State III
respiration.
As mentioned in
Chapter 1,
Oligomycin is an
ATP Synthase
inhibitor. It binds
the Oligomycin
Sensitive
Conferring
Protein (OSCP),
consequently
inhibiting State III
respiration. This
allows the protonmotive force to
build back up and
any oxygen
consumption
measured here is
a result of proton
leak across the
inner membrane.
FCCP is a weak
lipophilic acid
which acts as a
membrane
uncoupler. It
binds protons in
the IMS and
translocates them
to the matrix. The
rate of oxygen
consumed here
provides the
maximal
mitochondrial
respiration.
Rotenone is
added to inhibit
Complex I, as
discussed in
Chapter 1. Once
Complex I is

inhibited,
succinate is able
to feed electrons
into the ETC
through Complex
II. The rate of
oxygen
consumption here
provides
information about
State III Complex
II mediated
respiration
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Oxygen (nmol/ml)

A representative figure of an Oxytherm plot is as follows:

Time (min)
Figure 5.1 A representative figure of healthy mitochondria respiring
during a coupling experiment: Oxygen consumption within healthy
mitochondria.

150

Measurement of mitochondrial bioenergetics: Seahorse
Measurements of mitochondrial bioenergetics in isolated mitochondrial
were completed using a Seahorse XF24 Flux Analyzer as published previously
using slight modifications [447]. Stock mitochondrial substrates of 500 mM
pyruvate, 250 mM malate, 30 mM ADP, 1 mg/ml oligomycin-A, 1 mM FCCP,
1 mM rotenone and 1 M succinate were prepared and the pH was adjusted to
pH 7.2. The day before the planned experiment, a 24 well dual-analyte solid state
bio-sensor cartridge was hydrated with Seahorse XF Calibrant (pH 7.4) and
incubated in a non-CO2 incubator at 37 °C.
On the experiment day, the bio-sensor cartridge ports A through D were
loaded with 75ul of the appropriate mitochondrial substrates or inhibitors (Port A
= 8 x, Port B = 9 x, Port C = 10 x, and Port D = 11 x concentration made from
stocks and RB), and injected into the assay plate according to protocol procedure
to reach the final concentration of the compound (1 ×) in each well. The amount
of substrates/inhibitors loaded for each port is based upon the initial 525 μl RB
volume in the mitochondrial plate as follows: Port A – 75 μl (mixture of pyruvate,
malate and ADP), Port B – 75 μl (Oligomycin A), Port C – 75 μl (FCCP), and Port
D – 75 μl (rotenone and succinate). Once the bio-sensor cartridge was loaded
with all of the experimental reagents it was placed into the Seahorse XF24 Flux
Analyzer for automated calibration.
During the calibration phase, the Seahorse Standard XF24e flux assay
plates were utilized for mitochondrial analysis. Isolated mitochondria (7μg) from
every experimental group were analyzed together on a single plate.
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Mitochondrial samples were re-suspended in 50 μl RB and added in
experimental wells whereas background control wells contained 50 μl of RB
without mitochondria. Once every well was loaded, it was centrifuged for 4
minutes at 3,000 rpm room temperature. Following the centrifugation of the
plates, 475 μl (37 °C) of pre-warmed RB was gently added to each well for a final
volume of 525 μl per well. Plates were then placed into the calibrated Seahorse
XF24 flux analyzer for mitochondrial bioenergetics analysis after the sensor
cartridge calibration was concluded.
An optimized protocol was utilized for the analysis of bioenergetics
function in purified mitochondria using the Seahorse Biosciences XF24 Flux
Analyzer. The protocol contains sequential and/or cyclic steps of a cartridge
probe calibration, mixing substrates in the assay system, a delay for some time,
injections of substrates/inhibitors and then measurement of the oxygen
consumption rates (OCR) as elaborated upon previously [447].
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TABLE 5.3 Protocol for mitochondrial coupling studies
Time
Elapsed Procedure
Reason
Potential
Time
Issues
Calibration
-30
Calibrate Calibration of
minutes
Biosensors
the
biosensors,
measuring
standard
Oxygen and
pH
Insert
0
0
microplate
minutes
minutes
Equilibration
12
12
2 minutes
Allows
minutes
minutes
Mix x 3
samples in
microplate to
adjust to
temperature
2 minutes
changes.
Wait x 3
Consists of 2
minute mix
and a 2
minute wait
which is
repeated 3
times.
Basal
1
13
Mix
Measures the
Respiration
minutes
minutes
State I
respiration.
1:30
14:30
Wait
No
minutes
minutes
substrates,
only
2:00
16:30
Measure
mitochondria
minutes
minutes
5mM
~30
17
Inject Port
This step
When
Pyruvate
seconds
minutes
A
measures
running this
2.5mM
State IIIP/M
step, it is
25
17:25
Mix
Malate
mitochondrial crucial to go
seconds
minutes
1.0mM ADP
respiration. It back to the
0
17:25
Wait
will produce
raw O2
seconds
minutes
the electron
levels to
2:00
19:25
Measure
rich NADH
assure that
minutes
minutes
molecules
you have
leading to a not depleted
charged inner the oxygen
mitochondrial stores. This
Step

153

Mix 1

1
minute

20:25
minutes

Mix

~30
seconds
25
seconds
0
seconds
4:00
minutes

20:55
minutes
21:20
minutes
21:20
minutes
25:20
minutes

Inject Port
B
Mix

Mix 2

1 minute

Mix

4uM FCCP

~30
seconds
10
seconds
0
seconds
4:00
minutes

26:20
minutes
26:50
minutes
27:00
minutes
27:00
minutes
31:00
minutes

1uM
Oligomycin

Wait
Measure

Inject Port
C
Mix
Wait
Measure
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membrane
through
Complex I
while
providing the
ADP
necessary to
allow ATP
Synthase to
make ATP
Helps to reequilibrate
the system to
prepare for
the next
substrate

will lead to
errors in
your
calculated
OCR values

Sensors
needs to reequilibrate
to ambient
O2 in order
to read
effectively. If
this step is
skipped,
sensor can
drop below
its threshold
of reading
O2
This step
One has to
measures the assure that
State IV
the O2
respiration. consumption
Any oxygen
has
consumption
plateaued
here is the
before using
result of
the values to
proton leak
calculate
across the
your OCR
membrane
Same as
Mix 1
This step
Similar issue
measures the
seen here
State V
as seen with
respiration.
the injection
This is the
of Port A.
measurement Make sure
of O2
you have
consumption not depleted
when it is a
oxygen

Mix 3

1 minute

0.1uM
Rotenone
10mM
Succinate

~30
seconds
25
seconds
0
seconds
4:00
minutes

32:00
minutes
32:30
minutes
32:55
minutes
32:55
minutes
36:55
minutes

Mix
Inject Port
D
Mix
Wait
Measure
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uncoupled
from ATP
production
and is
defined as
the Maximal
Mitochondrial
Respiration
Same as
Mix 1
This step
measures
State Vsucc
mitochondrial
respiration. It
will produce
the electron
rich FADH2
molecules
leading to
activation of
the ETS
through
Complex II
while
inhibiting
Complex I
with
Rotenone

levels when
your OCR is
calculated.

Mitochondrial oxygen consumption rates (OCR) rates were recorded in the
absence or the presence of various mitochondrial substrates/inhibitors which
were added from port A to port D. The data files collected from each experiment
were analyzed and reported as percent OCR (% OCR) using GraphPad Prism 6
software package (GraphPad Software, Inc. La Jolla, CA).
Reactive Oxygen Species:
Mitochondrial ROS production was measured using 25uM 2’-7’dichlorodihydro-fluorescein diacetate (DCF) purchased from Molecular Probes
(Eugene, OR) (excitation 485nm, emission 528nm) in the Biotek Synergy HT
plate reader as described by [300, 301, 313, 418]. 25ug of isolated total
mitochondria were added to the a 96 well plate with 100uL of a mixture of RB,
5mM pyruvate, 2.5mM malate. Plate was warmed to 37oC within the plate reader.
DCF was added and the plate was incubated for 15 minutes. ROS production
was then calculated as the maximum DCF fluorescence expressed in arbitrary
fluorescence units. ROS production in the presence of oligomycin, which will
produce the maximal ROS production, and FCCP, which will produce the least
amount of ROS production, was also determined to assure that the
measurements were within the range of the ROS indicator.
Histological Analysis:
Animals were anesthetized using FatalPlus and immediately perfused with
saline followed by 4% paraformaldehyde. The brains were removed and placed
in 4% paraformaldehyde and 30% sucrose solution in PBS for 24hrs. After 24hrs,
the brains were transferred to a 30% sucrose PBS buffer solution without
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paraformaldehyde. 35uM coronal sections were cut with a freezing microtome
throughout the rostral caudal extent of the damaged cortex. Sections were
stained with cresyl violet and subjected to image analysis for lesion volume
assessment. Quantitative assessment of cortical damage employed a blinded
unbiased stereological protocol using the cavalieri method as previously
described. All slides were assessed blindly with respect to treatment group using
Image J for simple ROI analysis of cortical sparing.
Adjusted Neurological Severity Score:
Injured wild-type or mitoNEET null mice had functional recovery tested
using the adjusted neurological severity score (aNSS). This 14-point test
measures coordinated motor function and balance as a measurement of motor
function/recovery following injury. One day prior to injury, all animals were trained
to traverse elevated beams of 3, 2, 1, and 0.5 cm width and a 0.5 cm diameter
rod. At 1 hour, 24 hours, 3 day and 5 days post-injury, mice were allowed to
traverse the beams and points were deducted for footfalls, hanging upside-down,
an unwillingness to traverse the beam or falling off the beam.

Copyright © Heather Marie Yonutas 2016
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CHAPTER 6: SUMMARY AND CONCLUSIONS
With over 150 years of research into mitochondria, it is now well-accepted
that these once ill-defined bioplasts are crucial for cellular homeostasis. Their
role within the cell transcends mere ATP production. As more than the
proclaimed cellular “Power Plants”, these organelles are also important in
calcium cycling, the generation of reactive oxygen and nitrogen species and play
an integral role in apoptotic and necrotic cell mediated death pathways. Because
of their importance in overall cellular homeostasis, mitochondrial dysfunction has
been linked to many diseased states including Diabetes, Parkinson’s Disease,
Alzheimer’s Disease, Amyotrophic Lateral Sclerosis and, most important to this
dissertation, Traumatic Brain Injury. Mitochondria function has also been found to
be altered in models of aging, hinting to a possible mechanism as to
neurodegenerative diseases which generally appear in aged population.
Mitochondria are essential for appropriate metabolism and energy flow
within neurons but they have also been found to contribute to metabolic mediated
oxidative stress and for the initiation of cell death. Because of this, mitochondria
have been proposed as a therapeutic target in models of aging and Alzheimer’s
Disease, AD. With mitochondria being a key player in metabolism, dietary
interventions and supplementations with various antioxidants and mitochondrial
co-factors have been proposed to target mitochondrial dysfunction in order to
avoid age and AD related deficits, however the results from these studies have
been controversial.
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Oxidative damage seems to be a consistent feature seen in models of
aging [156-159]. The brain is particularly vulnerable to oxidative damage as a
result of it consuming approximately 20% of the body’s total oxygen, having a
high content of polyunsaturated fatty acids and lower levels of endogenous
antioxidant activity relative to other tissue [104-106]. Normal metabolic processes
result in the release of reactive oxygen species (ROS), which in turn can lead to
oxidative damage to proteins, lipids, DNA and RNA [156]. Since mitochondrial
are also a primary production site for ROS [163], these organelles become
particularly vulnerable to oxidative damage [164]. It has been hypothesized that
the combination of mitochondrial dysfunction and production of ROS may be a
key contributor to the deleterious effects of aging on the brain [14, 167, 173-179].
In addition to playing a role to the deficits seen with aging, mitochondria
dysfunction is also thought to be hallmark feature with this secondary injury
cascade in TBI, in which a similar mechanism has been proposed.
Similar to aging models, traumatic brain injury is another state that seems
to be plagued with mitochondrial dysfunction. Due to the heterogeneous nature
of this disease, experimental modeling has been challenging leading to the
invention of numerous injury paradigms in order to encompass a full range of
what is seen clinically. The rodent model of TBI that shows the most apparent
mitochondrial dysfunction is the controlled cortical impact. This is likely a result
of the focal nature of the injury which allows scientists to isolate tissue only
undergoing the secondary injury cascade. It is this tissue, which surrounds the
impact site and is defined as the penumbra and core tissue, that has been
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highly investigated for therapeutic interventions in an attempt to avoid the nonmechanical tissue damage that occurs following the primary injury.
The current dogma within the TBI literature is that following injury,
excitatory amino acids are released into the extracellular space in a
dysregulated manner. This leads to excitation of nearby neurons causing
pathogenic influxes of calcium. Mitochondria buffer this calcium leading to intramitochondrial changes in the redox potential and consequently the initiation of
oxidative stress. This oxidative stress is thought to lead to lipid peroxidation and
protein damage, similar to what has been proposed in aging models. This
oxidative stress was traditionally thought to be irreversible however work within
this dissertation project proposes a mechanism of mitochondrial dysfunction that
is enzymatically regulated and not due to vast oxidative damage, as originally
hypothesized [327].
After over 15 years, mitochondrial studies in the field of TBI have
concluded a well-accepted time course of mitochondrial dysfunction. Following a
focal injury significant dysfunction is seen at 1 hour post-injury and persists out to
48 hours, peaking around 12 to 24 hours [311, 348, 350, 363]. Still till today, the
mechanism behind this dysfunction is debated. As mentioned previously, the
current dogma proposes a mechanism which leads to irreversible oxidative
damage. However, as seen in Figure 4.4, pioglitazone, a drug which has been
shown to improve mitochondrial dysfunction, is able to improve mitochondrial
function when given at 12 hours post-injury, a time-point linked to maximal
mitochondrial dysfunction. In addition to pioglitazone, the use of an alternative
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biofuel called beta-hydroxybuterate, which is able to feed directly into Complex I,
effectively skipping any metabolic processes upstream up of Complex I, is also
able to increase mitochondrial function when given ex vivo.
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Figure 6.1 BHB intervention following injury can improve mitochondrial
respiration: In this experiment, BHB was given at 24 hours ex vivo in
mitochondria. BHB was able to increase mitochondrial respiration showing that
mitochondria are not completely damaged, rather inhibited at a point upstream
of Complex I.
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In healthy, uninjured, cortical tissue, Pyruvate Dehydrogenase, PDH, is
traditionally thought to be the gatekeeper of mitochondrial respiration [448].
Therefore, it was only reasonable to hypothesize the the limiting step that occurs
upstream of Complex I leading to inhibited respiration following injury would be
PDH. However, as seen by Opii et. al., PDH activity does not significantly
decrease following injury [343].
If not PDH, then what? Well, insight into this question may have surfaced
in 2004 when Colca et al discovered a novel mitochondrial protein which is now
hypothesized to be a Redox sensitive switch which is able to modulate
mitochondrial respiration [434, 449-452]. Work from Roberts et. al. has found
that mitoNEET is able to increase Glutatmate Dehydrogenase activity [83].
With compelling evidence showing mitoNEET as a redox switch and
showing mitoNEETs direct positive effects on GDH activity, it proposes a theory
in that GDH mediates mitochondrial respiration through mitoNEET activity. This
activity is then inhibited during high oxidative states, such as during calcium
cycling and following injury to the cortical tissue, leading to decreased
substrates feeding into the electron transport chain and therefore inhibiting state
III mediated respiration as seen with this research. When using a mitoNEET
ligand, such as NL-1 or pioglitazone, mitoNEET activity is increased during this
inhibitory state leading to increase mitochondrial respiration resulting in
increased cortical sparing and functional recovery.
From an evolutionary perspective, GDH is a highly modulated enzyme
that has been previously linked to mitochondrial function through the production

163

of NADH and α-ketogluterate from glutatmate and NAD+. It is thought that this
protein is an evolutionary byproduct from protozoa, which used this enzyme as a
sensor in its antenna in order to sense its environment and avoid encounters to
dangerous environments [453-456]. This information leads to a model as seen
below:
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Figure 6.2 Thesis Overview: This diagram proposes the mechanism which is hypothesized for
mitoNEET. mitoNEET targeting pharmacological treatments such at pioglitazone or NL-1 are able to
activate mitoNEET, which leads to Glutamate Dehydrogenase (GDH) activity. Under normal, homeostatic
conditions, mitoNEET activates GDH. Following a redox change within mitochondria, mitoNEET loses its
activity leading to an inhibition on GDH and therefore decreased mitochondrial respiration.

Future work within this project is ample. At this point, an in depth analysis
into GDH activity following injury needs to be completed, since the current
research related to GDH activity following TBI is limited and possibly nonexistent.
One will need to the hypothesis that pioglitazone’s ability to improve functional
recovery and increase tissue sparing following moderate CCI is dependent upon
GDH activity, which is modulated through mitoNEET. To further expand this
study, one will need to test whether NL-1, the mitoNEET specific ligand, can
reproduce the same effects as pioglitazone. The rationale behind this is that our
data supports the hypothesis that pioglitazone can significantly increase
mitochondrial bioenergetics following TBI resulting in increased tissue sparing
but does not provide the same degree of neuroprotection in mitoNEET -/- mice.
The literature also shows that pioglitazone binds mitoNEET, that pioglitazone
confers neuroprotection in mice after TBI at 1.0 and 10mg/kg and that GDH is
activated by interactions with mitoNEET. I have also demonstrated that the
mitoNEET ligand (NL-1) can confer neuroprotection following TBI. These data
drive the novel hypothesis that pioglitazone neuroprotection following TBI is
dependent upon its interactions with mitoNEET.
The experimental designs for these studies should assess GDH activity
following injury in addition to neuroprotection, through tissue sparing and
behavioral outcomes, following moderate CCI in mice administered the optimal
dose of a known GDH activator and/or inhibitor. Adult wild-type (+/+) and
mitoNEET null (-/-) male mice, should be subjected to either a sham surgery or
moderate TBI and either sacrificed at 24 hours post-injury for GDH activity
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studies or allowed to survive for 30 days, with naïve mice included for behavioral
outcome measures, depending on the cohort. Animals should all receive
intraperitoneal (i.p.) injections of vehicle or the 10mg/kg pioglitazone or NL-1 or
the ideal dosage of GDH activator and inhibitor at 15 minutes post-injury, in
accordance with their grouping. Changes in cortical and hippocampal
morphology should be assessed longitudinally (days 7, 14 and 28 post-injury)
using parametric T2 weighted imaging and apparent diffusion weighted
coefficients from DTI in addition to employing unbiased stereology at 30 days
post-injury. The extent of cortical sparing should be measured in a blinded
fashion using the variations in signal intensities at the region of interest, ROI.
These ROI measurements will be hand drawn and calculated with ImageJ.
Behavioral measures should include motor and cognitive function to assess the
degree of functional recovery as a result of treatment, employing both the
Adjusted Neurological Severity Score (aNSS) and Morris Water Maze (MWM).
Recovery of motor function will be assessed using the NSS at 1 hr, 24 hr, 72 hr,
and 120hrs after CCI or sham injury.
Additionally, since GDH is tightly linked to insulin production, which has
not been investigated within this paradigm. However, in a study completed by
Davis, it was found that insulin injections at 3 hours post-injury lead to rapid
death in a rodent model of CCI injury and did not increase cortical sparing or
functional recovery following injury. It is well accepted that metabolic dysfunction
occurs following injury and therefore further research into important metabolic
signaling molecules, like insulin, should be further investigated as well.
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Lastly, and seemingly most important to this study, is that further studies
need to completed in order to investigate the hypothesis that mitoNEET is a
redox sensitive mitochondrial protein that is able to modulate mitochondrial
function (“switching” them on and off) during times that redox potential has
shifted to a potentially pathogenic state. We currently understand that following
TBI, calcium dysregulation occurs leading to changes in the redox potential of
mitochondria. We also know that mitoNEET is able to inhibit mitochondrial
respiration. Research from this study showed the mitoNEET null mitochondrial
did not experience the same extent of mitochondrial respiration depression
when calcium was added ex vivo, compared to mitoNEET containing
mitochondrial. Therefore, mechanistic studies using mitochondria need to be
further investigated to determine if mitoNEET is indeed the “switch” that we think
it is.

Copyright © Heather Marie Yonutas 2016
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